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Abstract 
In multicellular eukaryotes, G protein-coupled receptors (GPCRs) play important roles in 
intercellular communication and in the perception of environmental conditions. They bind to 
various classes of ligands, including hormones, a light-sensitive compound, pheromones and 
neurotransmitters. Upon binding, they activate signaling pathways, thus ultimately causing a 
cellular response. A better understanding of GPCR signal-transduction mechanisms would 
improve our knowledge about fundamental processes in eukaryotic cells and it would facilitate 
the development of new medicine. 
Low expression levels and instability in solution have limited structural insights to very 
few selected members of this large protein family. It is particularly challenging to express GPCRs 
in prokaryotes, such as E. coli – a problem that renders many biophysical experiments 
impossible. Previously, researchers in the Plückthun laboratory developed directed evolution 
methods in E. coli, which generated neurotensin receptor 1 (NTR1) variants with significantly 
increased expression levels. In order to learn more about NTR1 and to prove the applicability of 
the evolutionary approach to structural biology, it was the goal of this doctoral work to 
determine the crystal structure of an evolved GPCR variant. 
A novel and unique purification procedure in the GPCR field was developed, which is 
based on a disposable, high-affinity ligand column and allowed the isolation of more than 10 mg 
of functional receptors directly from solubilized E. coli cells (no membrane preparation). The 
economical and time-efficient strategy was the foundation for the vapor diffusion crystallization 
of four constructs of three different evolved NTR1 variants bound to the neurotensin agonist.  
Initial purification problems using standard IMAC procedures also inspired the development of 
further evolution methods, selecting directly for long-term stability in detergent micelles. The 
variant TM86V that yielded the highest resolution structure at 2.75 Å was functionally 
characterized. The crystallized constructs exhibited residual ligand-dependent signaling, 
internalization and wild-type-like agonist and antagonist affinities. The structures of the three 
different NTR1 variants TM86V, OGG7 and HTGH4 are fully consistent with all biochemically 
defined ligand-contacting residues, thus underlining the applicability of directed evolution 
technologies to GPCR structural biology.  
All structures are highly similar, but they exhibit major differences to another NTR1 
structure of a signaling-deficient variant that was fused to T4 lysozyme for structure 
determination (PDB-ID: 4GRV). The differences are observed in the ligand-binding pocket and at 
the cytosolic region, where the amphipathic helix 8 in the signaling-deficient NTR1 variant is 
surprisingly absent. An analysis of helix 8 stability determinants between NTR1 and other 
crystallized GPCRs suggests that the occupancy of the canonical position of the amphipathic 
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helix is reduced to various extents in many receptors, and we have elucidated the sequence 
determinants for a stable helix 8. Our analysis also provides a structural rationale for the long-
known effects of C-terminal palmitoylation reactions on GPCR signaling, receptor maturation 
and desensitization. 
In the last part of this dissertation, the purification methods were applied to obtain the 
first NMR spectra of isotope-labeled, fully deuterated and functionally expressed GPCRs. Most 
backbone amide resonances could be observed in a 1H-15N TROSY spectrum after detergent 
optimization and the spectral quality implied that assignments are possible, suggesting that 
unique data on the dynamics of a model GPCR might be obtained in the near future. 
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Zusammenfassung 
In mehrzelligen Eukaryoten übernehmen G-Protein-gekoppelte Rezeptoren (GPCRs) 
Kernaufgaben der interzellulären Kommunikation und bei der Wahrnehmung von Signalen der 
Umwelt. Sie binden sehr unterschiedlichen Typen von Liganden, zum Beispiel Hormone, 
Chromophore, Pheromone und Neurotransmitter. Die extrazelluläre Liganden-Bindung führt zur 
Aktivierung von intrazellulären Signalkaskaden und schlussendlich zu einer zellulären Reaktion. 
Mehr Erkenntnisse über den Signal-Übertragungs-Mechanismus der GPCRs würden unser 
Verständnis fundamentaler Prozesse in eukaryotischen Zellen verbessern und die Entwicklung 
neuer Medikamente vereinfachen. 
Tiefe Expressionsniveaus und Instabilität in Lösung haben dazu geführt, dass nur wenige 
GPCRs strukturell untersucht werden konnten. Im Besonderen ist es schwierig diese Rezeptoren 
von Prokaryoten, wie zum Beispiel von E. coli, herstellen zu lassen, was einige biophysikalische 
Experimente nahezu verunmöglicht. Vor Beginn dieser Doktorarbeit haben Wissenschaftler des 
Plückthun-Labors sogenannte „zielgerichtete Evolutionsmethoden“ (directed evolution) in E. coli 
entwickelt, die es erlaubten, besser herstellbare Neurotensinrezeptor 1 (NTR1) Varianten zu 
generieren. Um neue strukturelle Erkenntnisse über NTR1 zu generieren und um die 
Anwendbarkeit der gerichteten Evolutionsprinzipien zu beweisen, war es das Ziel dieser 
Dissertation, eine hochaufgelöste Kristallstruktur einer evolvierten Rezeptorvariante zu 
ermitteln. 
Basierend auf einer Einweg-Ligandensäule, wurde eine bisher einzigartige 
Reinigungsmethode im GPCR-Forschungsfeld entwickelt, die die Anreicherung von mehr als 10 
mg funktionalem Rezeptor direkt aus aufgelösten E. coli Zellen ohne Membranpreparation 
erlaubt. Diese ökonomische und Zeit-effiziente Strategie war die Grundlage für die 
Kristallisation von vier Agonist-gebundenen Rezeptorkonstrukten dreier unterschiedlicher 
NTR1 Varianten. Anfängliche Reinigungsprobleme mit Standard-Methoden haben zudem die 
Entwicklung alternativer Evolutionsmethoden inspiriert, die direkt auf dauerhafte 
Rezeptorstabilität in gelöster Form selektieren. Die NTR1 Variante TM86V ergab die 
höchstaufgelöste Struktur (2.75 Å) und wurde deshalb funktionell charakterisiert. Die 
kristallisierten Konstrukte zeigten trotz Mutationen eine verbleibende Liganden-abhängige 
Signalübertragung, Internalisation und Wildtyp-ähnliche Agonist- und Antagonistaffinität. Die 
Strukturen der drei unterschiedlichen NTR1 Varianten TM86V, OGG7 und HTGH4 entsprechen 
allen biochemisch definierten Ligandkontakten und belegen deshalb die Anwendbarkeit der 
gerichteten Evolution für die Strukturbestimmung von GPCRs. 
Alle unsere Strukturen sind sich sehr ähnlich, aber sie unterscheiden sich stark von einer 
anderen NTR1 Struktur, die mithilfe einer Lysozymefusion bestimmt wurde, welche keine 
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Signalübertragung zulässt (PDB-ID: 4GRV). Die Unterschiede sind in der 
Ligandenbindungstasche und beim intrazellulären Bereich, wo zum Beispiel die ganze 
amphipathische Helix 8 entweder existiert oder wie beim nicht-funktionalem Konstrukt 
überaschenderweise abwesend ist. Eine Analyse der strukturellen Einflussgrössen bezüglich 
Helix 8-Stabilität ergab, dass die Besetzung („occupancy“) der typischen Helix 8 Position in 
verschiedenen GPCRs unterschiedlich stark ist. Des Weiteren erklärt sie, wie die bekannten 
Effekte der C-terminalen GPCR-Palmitoylierungsreaktionen auf die Signalübertragung, die 
Rezeptormaturierung und Desensitierung entstehen könnten. 
Als letzter Teil dieser Arbeit wurde die entwickelte Reinigungsmethode eingesetzt, um die 
ersten NMR Spektren voll deuterierter, isotopenmarkierter und funktional hergestellter GPCRs 
zu messen. Die meisten Amid-Resonanzen des Proteinrückgrats sind in einem 1H-15N TROSY 
sichtbar nach Detergenzoptimierungen. Dies deutet darauf hin, dass eine Zuordung der meisten 
Resonanzen zu spezifischen Aminosäuren möglich ist und neue Einsichten bezüglich GPCR-
Dynamik nun zugänglich werden könnten. 
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1.1.  Historical aspects 
From a human perspective, the diversity of life on earth can be fascinating. Approximately 
8.7 million distinct eukaryotic species exist1 and our perceptional limits are challenged by their 
variability in morphology, lifestyle and organization at the tissue and cellular levels. Charles 
Darwin offered in 1859 an explanation for the existence of diverse life forms and suggested that 
they arose by common descent from evolving populations due to natural selection2. After the 
modern evolutionary synthesis, which combined his concepts, genetics and a body of evidence 
from other fields (1936-1947), we have arrived in the age of molecular life sciences to date. Like 
Darwin, who observed his first signs of evolution during the long and hazardous voyage on HMS 
Beagle, many modern researchers are setting out to another difficult journey these days – the 
exploration of life at the subcellular scale. Surprisingly, Darwinian principles – once generating 
today’s diversity – are applied now to explore the living at molecular levels. 
1.2.  G protein-coupled receptors 
One of the best described aspects among the tree of life is the distinction between 
prokaryotic and eukaryotic cells. In contrast to bacteria and archaea, eukaryotic cells contain a 
nucleus and other organelles like the endoplasmatic reticulum or mitochondria. Apparently, 
they are also different at the level of the genome, since many “younger” protein families are only 
present in one or the other domain. G protein-coupled receptors (GPCRs), for example, which 
exist at the interface of a cell’s external and internal environment, appear to be restricted to 
eukarya3. In this domain and in particular in metazoans, however, they have evolved to play 
major physiological roles: They mediate most cellular responses to neurotransmitters and 
hormones and at the same time, they are crucial for vision, olfaction and taste4. In humans, more 
than 3 % of the open reading frames encode GPCRs, which makes them to the largest membrane 
protein family in this species5.  
1.2.1.  Structure 
GPCRs consist of seven transmembrane-spanning α-helices that are separated by extra- 
and intracellular loop regions (Figure 1.1). In vertebrates, they are commonly divided into five 
classes based on their structural and sequence similarity: class A (rhodopsin), class B (secretin), 
class C (glutamate), adhesion and Frizzled/Taste2. Here, the focus will be on class A GPCRs, 
which is by far the largest and most diverse class in terms of ligands. All members of this class 
exhibit small intra- and extracellular regions, which can be highly variable on the sequence level. 
Some motifs in the transmembrane region are, however, conserved to some extent, implying 
shared structural features and activation mechanisms (Figure 1.1). 
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Figure 1.1  Overall architecture of class A GPCRs. A, Snake-plot of bovine rhodopsin, which was the first 
GPCR yielding high resolution crystal structures6. The most conserved motifs are depicted in yellow. Note 
that the termini, the loops and also parts of the transmembrane helices (TMs) are highly variable among 
class A GPCRs. As evident from the illustration, rhodopsin exhibits not all of the most conserved motifs 
(see TM1), which exemplifies the low sequence conservation of GPCRs. Extracellular parts are frequently 
glycosylated (not shown) and many GPCRs encode one or more palmitoylation sites (cysteines) in close 
proximity to the amphipathic H8 near the C-terminus (not the case for rhodopsin). B, view parallel to the 
membrane plane on the GPCR helical bundle in a prototypical inactive conformation (loops and termini 
are omitted). TMs are colored from N-terminus to C-terminus (green to red). C, Extracellular (left) and 
intracellular (right) view onto the transmembrane bundle. Note that class A GPCRs exhibit a circular and 
almost sequential arrangement of TMs. The main irregularity regarding sequential TM stacking are the 
exchanged intracellular endings of TM3 and 4, which is due to a pronounced tilt of TM3 relative to the 
other helices. 
 
1.2.1.  Function 
The classical function of GPCRs is the coupling of an extracellular signal to the activation of 
heterotrimeric G proteins, which leads to the modulation of downstream effector proteins. 
Taking neurotensin receptor 1 (NTR1) as an example, the binding of neurotensin (or the related 
neuromedin N peptide) in the extracellular half of the TM bundle, leads to guanine-nucleotide 
exchange factor (GEF) activity at the GDP-bound heterotrimeric G protein7. After nucleotide 
exchange to GTP, the heterotrimeric G protein dissociates into α- and βγ-subunits, which in turn 
stimulate or inactivate the production of second messengers at downstream signaling partners8.  
At least 16 different G protein α subunits exist9 10, which can be categorized into either Gαs 
Gαq, Gαi or Gα12. In addition five β and eleven γ subunits11; 12 are encoded in mammals and 
4 CHAPTER 1  
together, the three subunits form trimeric complexes of various stabilities. GPCRs exhibit 
preferential coupling to one or several heterotrimeric G proteins and vice versa.  NTR1, for 
example, was described to couple mainly via Gq, which triggers production of inositol 1,4,5-
trisphosphate (IP3) by the activation of phospholipase C (Figure 1.2A)13, but also via Gs and Gi 
that modulate the activity of the adenylate cyclase and hence the level of cAMP in the cytosol 
(Figure 1.2A)14-16. The precise signaling behavior of each GPCR is likely dependent on the 
physiological context – e.g. on the expression levels of alternative signaling partners.  
In humans, more than 600 different class A GPCRs are encoded17 and expressed depending 
on the cell type, developmental stage and additional factors. The various G protein subunits can 
potentially combine into several hundred heterotrimers with various coupling properties in 
terms of GPCR preference and downstream effectors. Many heterotrimers have already been 
detected and were proven to couple to GPCRs (personal communication, M. Hillenbrand). This 
diverse set of signaling modules may represent a key adaptation of multicellular eukaryotes, as 
it allowed fine-tuned intercellular communication and thus a complex, well-balanced interplay 
of highly specialized tissues and organs18. 
An important feature of GPCRs is their waning responsiveness to repeated stimulation 
with agonists, a process termed desensitization. One part of this process is the internalization of 
activated receptors by endocytosis, which was also shown to occur for NTR1 upon agonist 
binding (Figure 1.2B)19; 20. Desensitization in general is usually initiated by GPCR kinases that 
specifically phosphorylate residues at activated GPCRs (mostly serines and threonines in 
proximity to the C-terminus after helix 8). Phosphorylated, agonist-bound receptors are then 
recognized by β-arrestins, which prevent G protein binding and thus block this type of 
signaling8. In recent years, it became apparent that β-arrestin-binding is the key trigger of 
internalization, as it initiates clathrin-mediated endocytosis, followed by either trafficking the 
receptor-β-arrestin complex to the lysosome or by receptor recycling to the cell membrane. 
Interestingly, β-arrestin can also signal via alternative “non-classical” pathways, for example via 
tyrosine or mitogen-activated protein (MAP) kinases8; 21; 22. Many GPCRs can exhibit preferential 
signaling, either towards the classical, G protein-mediated route or via β-arrestin. On one hand, 
the “choice” of signaling pathways depends on the particular kind of ligand bound to the 
receptor – a broadly accepted concept termed “biased signaling”23 – and on the other hand, it 
depends on the expression levels of the signaling partners, making the response cell-type 
specific. 
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Figure 1.2  Overview on the most investigated signaling pathways of class A GPCRs. A, Gαs and Gαi 
regulate the cyclic AMP production, whereas Gαq activates phospholipase C to produce inositol 1,4,5-
trisphosphate (IP3) upon hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2). B, Receptor 
desensitization/internalization and alternative signaling behaviors are mediated by β-arrestins. Four 
types of β-arrestins are encoded in the human genome: Arrestin1 and arrestin4 are expressed in retinal 
rods and cones, respectively, whereas arrestin2 (also called β-arrestin1) and arrestin3 (also called β-
arrestin2) are ubiquitously distributed and interact with most GPCRs8. 
 
1.2.1.  Activation mechanism 
As described above, at least 3 different types of proteins interact with the intracellular 
regions of activated GPCRs: Heterotrimeric G proteins, GRKs and β-arrestins. To date, mainly 
antagonist- or inverse agonist-bound GPCR structures are available, which represent inactive 
states that cannot bind to any signaling partner at the cytosolic side. Two types of high 
resolution data sets on GPCRs in complex with intracellular signaling partners were however 
obtained recently: First, rhodopsin bound to the C-terminal helix of the α-subunit of transducing 
(ocular heterotrimeric G protein)24-28, and second, the β2-adrenergic receptor (β2AR) in complex 
with the heterotrimeric Gs protein20. Comparing the inactive-state structures of both receptors 
with their respective structures in the G protein complex, it can be observed that in both cases 
TM6 – and to a smaller extent TM5 – shift outward at the intracellular side upon G protein 
binding. The center of the “open” cytosolic receptor region is occupied by the C-terminal helix of 
the α-subunit of the G protein, which represents the main interaction site of the two signaling 
partners (Figure 1.3A and B). As rhodopsin is not a typical GPCR (highly expressed in certain 
tissues, highly thermostable, no diffusible ligand, activated by light), the following discussion 
about GPCR activation will focus on β2AR.  
Numerous structures of β2AR were determined over the last 6 years and two interesting 
structural themes were observed: First, in the absence of G protein or G protein mimics, all 
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crystal structures of β2AR showed “closed” conformations at the intracellular side, which 
appeared to be incompatible with G protein binding. This came as a surprise, since the receptors 
were crystallized in different space groups, by different crystallographic techniques and in 
complex with different ligands of alternative pharmacologies (inverse agonists, antagonists and 
agonists). Second, the differences at the extracellular side between inverse agonist-bound 
structures and ternary complexes (agonist/β2AR/G protein) are extremely small (Figure 1.3A). 
How does signaling work, if only minor structural changes occur in the ligand-binding pocket 
and no active states can be observed at the G protein interacting surface? 
The Kobilka group, which determined most of the β2AR structures, proposed that the 
receptor exhibits a conformational ensemble of several distinct inactive and active states29. 
Using NMR30; 31 and double electron-electron transfer (DEER, personal communication, Aashish 
Manglik), they provided evidence for a destabilization of inactive states upon agonist binding. 
They further suggest that active states are not stabilized by agonist-binding, but only upon 
interaction with G protein. Unlike the highly specialized rhodopsin, which appears to be an 
efficient two-state, light-activated switch between relatively well defined inactive and active 
states32, β2AR may be a more versatile, albeit less efficient molecular machine. It appears to 
couple ligand-binding to several different signaling processes inside the cell by sampling an 
ensemble of conformations with alternative binding-specificities – a behavior that might be 
prototypical for GPCRs.  
An improved understanding of GPCR function will require a more detailed assessment of 
conformational dynamics, measurements of time-scales from milliseconds to seconds, 
computational efforts to rationalize these observations and the determination of further crystal 
structures of alternative receptors in complex with many cytosolic interaction partners, such as 
alternative G proteins, GRKs and β-arrestins. 
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Figure 1.3   A, Current model of GPCR activation based on the example of β2AR. A, Inactive (grey, 
carazolol-bound) and active (green, G s- and irreversible full agonist-bound) receptor superposition (PDB-
IDs: 2RH1, 3SN6). Note the large movement of TM5 and 6 at the cytosolic side (only observed in the 
presence of Gs) and the minor changes at the extracellular side. B, Receptor-Gαsβ1γ2 complex. For clarity, 
only the C-terminal helix of Gα is shown at the intracellular perspective (top). C, Suggested mechanism of 
β2AR activation. The mobility of cytosolic regions increases and extracellular regions sample less 
conformations upon agonist binding. The G protein stabilizes the active state. Note that the suggested 
destabilizing effect of the agonist on the inactive state is not evident from the energy landscape scheme. 
Panel C is an adapted Illustration from Nygaard et al. 2013 30. 
 
 
1.2.1.  Neurotensin receptor 1 
Neurotensin is a tridecapeptide (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) 
that was originally isolated from bovine hypothalamus in 197333 and subsequently from bovine 
intestine34. Like many neuropeptides, it fulfills a dual function as a neuromodulator in the 
central nervous system and as a local hormone in the periphery. In the brain, it exerts potent 
hypothermic and analgesic effects and it acts as an appetite suppressant. In addition, it 
modulates dopamine transmission and anterior pituitary hormone secretion35. It plays a role in 
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neuropsychiatric and neurodegenerative diseases36. In peripheral organs, neurotensin is an 
endocrine and paracrine modulator of the digestive tract and of the cardiovascular system. 
Furthermore, it was shown to act as a growth factor on cancer cells, suggesting that medical 
compounds targeting its signaling pathway are of high pharmacological relevance35. 
Three neurotensin receptors were identified (NTR1, NTR2, NTR3). NTR1 and NTR2 are 
class A GPCRs, whereas NTR3 (also termed sortilin37) is a single-transmembrane, multi-domain 
protein. Most of the described effects of neurotensin are mediated by NTR1, which was shown to 
interact with the six C-terminal amino acids of neurotensin (NT8-13). Northern blot analysis 
confirmed NTR1 expression in rat and human brain and intestine35; 38. Specifically in the central 
nervous system, high levels of NTR1 mRNA were found in several areas, including nucleus 
basalis magnocellularis, suprachiasmatic nucleus, substantia nigra and in the neurons of the 
diagonal band of Broca.  
NTR1 interacts with several different signaling partners. It was shown to activate 
phospholipase C via coupling to Gq and to modulate adenylyl cyclase activity via Gi and Gs40. 
Moreover, in primary cultured rat brain neurons, in neuronal cell lines and in CHO and COS cells, 
it was demonstrated that NTR1 internalizes upon agonist binding41. Internalization was 
impaired by the double-mutation at Thr422 and Tyr424 in the C-terminal tail, suggesting that 
these residues may be relevant for GRK or β-arrestin interactions42.  
The broad spectrum of interacting signaling partners is typical for GPCRs and considering 
the availability of several synthetic ligands of alternative pharmacologies and the medical 
potential of NTR1 targeting strategies, it is clear that this receptor is a promising GPCR 
representative for in-depth studies including structural investigations.  
 
1.3.  Membrane protein structure determination 
Understanding the molecular basis of life crucially depends on the availability of structural 
information at atomic resolution. In comparison to other biomolecules, high-resolution 
structural data on membrane proteins (MPs) is particularly scarce. Given that approximately 
26 % of human genes are encoding MPs43, it is striking that only 417 unique structures are 
available in the Protein Data Bank (September 2013)44. This contrasts to the total number of 
deposited, unique biomolecular structures, which is 20’879. Hence, it is evident that specific 
technical problems, related to MPs, are limiting structural characterizations. 
The most commonly applied technique for structure determination at atomic resolution is 
x-ray crystallography45. MP-specific difficulties in crystallographic projects are low heterologous 
overexpression levels and reduced stability in detergent solubilized-states compared to their 
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native membrane environment. Both problems hamper preparation of milligram quantities of 
homogeneous and active protein samples and thus limit the number of crystallization conditions 
that can be screened. Additional problems are related to the application of detergents for MP 
handling. High amounts of detergents trigger disadvantageous phase separations in vapor 
diffusion crystallization experiments46 and the presence of the detergent belt around 
transmembrane regions is a main reason, why MP crystals tend to have high solvent contents 
and poor diffraction47. 
 Miniaturization and the development of high-throughput crystallization robotics has 
facilitated biomolecular crystallography in general ways in recent years. At the same time, MP-
specific challenges were also tackled: First, by the development of novel membrane mimics, 
second, by the development of alternative crystallization methods and third, by the 
establishment of screening and protein engineering strategies that allow identification of 
suitable MPs for structural studies. 
1.3.1.  Alternative membrane mimics and the special case of GPCRs 
The most commonly applied amphiphiles for extraction of MPs from membranes and for 
mimicking the native hydrophobic environment during purification are detergents. Newstead et 
al. provided in 2007 an extensive analysis of published MP crystallization conditions and 
reported, among other findings, that the majority of published structures were obtained using n-
dodecyl-β-D-maltoside (DDM)48. The impression of DDM as a successful crystallization detergent 
may be biased to some extent, due to the fact that many MP crystallographers traditionally apply 
it as a first choice in crystallization trials49; 50. Nevertheless, it is apparent that DDM is one of the 
mildest available detergents and hence a promising candidate for crystallographic purposes.  
In a more recent report, Chae et al. (2010) introduced a novel type of detergent, which is 
built around a central quaternary carbon atom derived from neopentyl glycol and two 
hydrophilic head groups derived from maltose51. These, so called maltose-neopentyl glycols 
(MNGs), tend to have very low critical micelle concentration (e.g. 0.001 % (w/v) for MNG-3) and 
were described to be efficient solubilization agents. Further, Chae et al. reported that MNGs can 
provide superior stability to various types of membrane proteins (relative to DDM), including 
GPCRs, a succinate:quinone oxidoreductase and a light-harvesting complex51. Based on the 
application of MNG-3 during purification, several crystal structures of GPCRs were published in 
the last three years24; 52-59 and given the limited amount of time since Chae’s initial publication, it 
is likely that MNGs will soon be established as an important tool in MP research. 
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Figure 1.4   Chemical structures of n-dodecyl-β-D-maltopyranoside (A) and of lauryl neopentyl glycol (B). 
 
In spite of the preference of MP crystallographers for DDM, this particular detergent has 
never been successfully used for the crystallization of GPCRs in vapor diffusion experiments. 
This was true at the very beginning of this thesis in 2009, when only four unique structures were 
available (rhodopsin, β1-adrenergic receptor, β2-adrenergic receptor, A2A adenosine receptor), 
and it is now still the case after the publication of more than 20 different receptor structures60.  
One explanation for the particular behavior of GPCRs in crystallization trials is related to the 
unusually small intra- and extracellular regions of most of these receptors. Since DDM forms 
large micelles, it is likely that the hydrophilic regions of GPCRs are partially covered by the 
detergent and thus occluded from crystal contact formation. 
1.3.2.  Lipidic cubic phase crystallization 
One main strategy that was pursued to circumvent shielding effects of large micelles, was 
the application of lipidic cubic phase (LCP) crystallization, as it allows or favors crystal contact 
formation via transmembrane regions61; 62. Typically, reconstitution into the three-dimensional 
lipidic bilayer (the cubic phase) is performed using liquid monoolein and pure GPCRs in a mild 
detergent, such as MNG-3 or DDM. At 20°C, the cubic phase Pn3m forms spontaneously, when 
water (or aqueous protein solution) is mixed to liquid monoolein at the exact ratio of 1 to 1.5 63. 
Pn3m is bicontinuous, in the sense that it allows diffusion of solvents and of MPs in all 3 
dimensions – both are crucial requirements for crystallogenesis23. Once LCP is formed, it can co-
exist with excess aqueous solution (it does not dissolve), which is essential for crystal screening 
purposes. Hundreds of individual LCP boluses are usually covered by different crystallization 
solutions and the various solutes (salts, precipitants, buffering agents, etc.) diffuse into the LCP 
at different rates, thus exposing the reconstituted GPCRs to an array of changing solvent 
conditions over time. Interestingly, small-angle x-ray scattering experiments have clearly proven 
that the lipidic phase is indeed cubic after reconstitution and prior to crystallization. 
Nevertheless, the crystallized GPCRs reside always in a lamellar phase locally, which is evident 
from the exclusively parallel or antiparallel alignments of the GPCR transmembrane regions in 
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the crystal lattice (Figure 1.5). It is currently unclear, whether crystallization triggers the local 
transition to the lamellar phase or vice versa.  
The alignment of the transmembrane segments and the crystal contacts via these regions 
are important reasons for the comparably small solvent content that LCP crystals often exhibit. 
And this may in turn explain why crystals of this type frequently diffract to relatively high 
resolution (e.g. the structure of A2A adenosine receptor at 1.8 Å at a solvent content of 51 %64). 
A clear disadvantage is, however, that it is challenging to obtain datasets with “high” 
completeness (> 90 % in the highest resolution bin).  In many cases it was necessary to merge 
several small datasets, each covering only very few degrees of rotation. This has two LCP-
specific reasons: First, LCP crystals are often significantly more sensitive to radiation damage 
compared to crystals from vapor diffusion experiments (personal communication, William I. 
Weis and Kaspar Hollenstein), which reduces the applicable x-ray dose. In my opinion, this 
might be due to higher diffusion rates of radicals within the membranous phase compared to the 
aqueous phase in vapor diffusion experiment (more secondary radiation damage). And second, 
the goniometric crystal centering in the x-ray beam is often very difficult, due to the uneven LCP 
surface in the loop and the different refractive indices of air and LCP (crystals are almost 
impossible to see after harvesting and mounting to the beam). The crystals have therefore often 
to be localized by x-ray test exposures using a dens raster, which causes additional radiation 
damage65. As a result of difficulties in goniometric centering, crystals can exit the x-ray beam 
after very few degrees of rotation during data collection.  
The major disadvantage of the LCP methodology for GPCR crystallization is certainly the 
necessity of at least one soluble protein (or domain) to bridge the aqueous channels of the lipidic 
phase for crystal contact formation. In the vast majority of published structures, the intracellular 
loop 3 (IC3) was replaced by T4 lysozyme (T4L). This rendered the receptors signaling-inactive 
in all cases, as it prevented the interaction with the name-giving signaling partners (the G 
proteins). In one exceptional case, T4 lysozyme was attached to the GPCR N-terminus, but these 
crystals diffracted only to 4 Å, which might be due to the higher flexibility of the construct 
compared to the IC3 fusions66. The majority of high-resolution LCP structures are thus only 
obtained from GPCR-like hybrid molecules, not from G protein-coupled receptors and it is 
important to develop alternative strategies, which focus on the structure determination of 
signaling-active proteins. Structures of this type would likely shed light on novel aspects of GPCR 
signaling, due to a more reliable description of intracellular regions. 
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Figure 1.5   Example of LCP crystal packing (PDB-ID: 3VW7). Protease activated receptor 1 (PAR1, grey) 
fused to T4L (red) in complex with the antagonist vorapaxar (blue)67. These crystals diffracted to 2.2 Å 
and displayed a solvent content of 50.7 %, which is comparable to many soluble proteins (43 % on 
average68). The data exhibit a completeness of only 85 % in the highest resolution bin, in spite of the fact 
that datasets from 18 different crystals were merged. The space group is P212121. 
 
1.3.3.  Screening the diversity of life and alanine-scanning 
Advances in MP structural biology are not only due to the development of novel 
membrane mimics and because of improved LCP crystallization methods. Significant progress 
was also made at the level of the target proteins themselves in recent years. As mentioned 
above, low overexpression levels and reduced stability in detergent solution appear to be major 
factors that specifically counteract MP structure determination efforts.  Both of these factors are 
protein-specific characteristics, and hence, sequence-dependent features. 
A successful strategy for the identification of well-expressed and stable membrane 
proteins for structural biology is based on homology screening. Homology screens take 
advantage of the existing diversity of life, its common descent and the conservation of structure-
function relationships at the molecular level during evolution. Given a specific human MP of 
interest, researchers use the available genomic data to extract in silico an array of homologs by 
BLAST algorithms. Efficient methodologies have been established that allow cloning of hundreds 
of homologous sequences from various organisms into expression vectors69; 70, thus providing a 
basis for production and subsequent thermostability assessments or purification tests in high-
throughput formats. Novel high-resolution structures of previously poorly characterized 
membrane protein families, such as ion channels and ABC transporters, could be determined in 
this way7172; 73. Even if a homolog under investigation is only distantly related to the protein of 
interest, the overall architecture can be similar and the conservation of key functional residues 
is often a valuable basis to conclude on certain structural aspects of human counterparts and on 
their molecular mechanisms71; 74-77. 
EVOLUTION, GPCRS AND MEMBRANE PROTEIN TECHNOLOGIES 13  
 
Homology screens depend on the existence of related genes that have evolved over the last 
billions of years and on the availability of their sequences. By far the most genomes that were 
sequenced in recent years are of prokaryotic origin (approximately twenty times more than 
eukaryotic78) and it is thus not surprising that mostly structures of prokaryotic homologs could 
be solved using this approach. Another explanation for this fact may be the higher variability of 
environmental conditions in prokaryotic niches compared to the controlled and thus constant 
settings of the intercellular spaces in multicellular eukaryotes. Some prokaryotic MPs may have 
been naturally selected to exhibit high stabilities in order to withstand harsh conditions, such as 
high salt concentrations (halophiles) or hot springs (thermophiles), which would be favorable 
for structural studies. Based on these considerations, it appears that the vast majority of 
eukaryotic MP families are not promising targets for homology screens, as no related 
prokaryotic MP genes were identified so far (only 256 common families were described out of a 
total of 1762 eukaryotic MP families79). 
GPCRs, for example, which are uniquely eukaryotic MPs, may be very challenging targets 
for homology screening. But given their physiological importance, alternative strategies, such as 
alanine-scanning mutagenesis, were recently developed80. Using the alanine-scanning approach, 
the stability problem of GPCRs is tackled by the artificial introduction of hundreds of individual 
point mutations. Every wild-type residue of a GPCR (> 300 amino acids) is usually replaced by 
alanine (or leucine if alanine is the wild-type residue) and the resulting mutants are individually 
expressed and analyzed for thermostability in detergent solution. The most thermostable point 
mutations are subsequently combined in different pairs at the gene level and a novel round of 
expression and thermostability analysis is started. This process is repeatedly carried out until 
mutants with reasonably increased thermostability can be isolated, which are then subjected to 
structural studies. 
The alanine-scanning methodology has lead to the structures of several GPCRs, mostly 
using the mild LCP crystallization methodology and lysozyme fusions60; 80. One drawback of this 
method is however, that – despite of considerable mutagenesis and screening efforts – it is often 
challenging to increase GPCR thermostabilities sufficiently for vapor diffusion crystallization. 
Instead, residual signaling-activity (if any after mutagenesis) is entirely abolished by the 
inactivating lysozyme, which critically promotes LCP crystallization. Since the crystallized 
constructs are frequently signaling-inactive, many structural aspects – mostly those distant to 
the ligand – are not reliably representing functionally relevant GPCRs states19. Further, alanine-
scanning does not specifically tackle overexpression problems in heterologous systems, which is 
frequently an important limitation for GPCR structural research. 
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1.3.4.  Directed evolution for structural studies of GPCRs 
An interesting approach that focused on the GPCR overexpression problem was 
introduced by Casim Sarkar and other members of the Plückthun group in 200881. E. coli – being 
the most frequently applied and simple heterologous expression host for proteins in general – 
had never been successfully used for GPCR structure determination at that time. It was apparent 
that its inapplicability for the functional production of large quantities of receptors hampered 
scientific progress in the GPCR field. The basic motivation of Sarkar et al. was therefore to 
develop a method that can generate altered wild-type GPCR amino acid sequences with higher 
functional expression levels in E. coli.  
Briefly, genetic diversity was generated analogously to natural processes by random 
mutagenesis – albeit with a very high mutation rate, using error-prone PCR on a wild-type 
receptor gene. Approximately 109 different GPCR variants, carrying up to four different random 
mutations were subsequently transformed at once into E. coli. They were encoded on an 
expression vector, which provided an N-terminal maltose-binding protein (MBP) with a 
periplasmic signal sequence and an IPTG-inducible promotor. After induction of the cell pool and 
gentle permeabilization of the outer membrane, a fluorescent GPCR ligand was applied, which 
labelled preferentially those cells with high functional expression levels. This resulted in 
distinguishable phenotypes that were linked to their corresponding genotypes – a core 
requirement of evolution. As a selection pressure, fluorescence-activated cell sorting (FACS) was 
applied, which enriched the most expressing cells from a population of approximately 100 
million “individuals” (108 cells/h can be sorted).  This mutagenesis and selection cycle was 
repeatedly carried out and generated an array of GPCR variants with high functional expression 
levels in E. coli (Figure 1.6). 
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Figure 1.6  Directed evolution approach that improved the expression levels of neurotensin receptor 1 
(10-fold), tachykinine receptor NK1 (>10-fold), α1A adrenergic receptor (>10-fold) and α1B adrenergic 
receptor (<10-fold). One E. coli cell of a library containing approximately 109 members is depicted at stage 
(2) and (4). Its inner and outer membranes are illustrated by 2 black smoothened rectangles. An 
expressing GPCR variant and its corresponding plasmid are depicted in yellow. The fluorescent ligand 
(black empty circle) is labeled with a fluorescent dye (blue asterisk). The FACS readout is forward scatter 
(FSC, a measure of cell size) and fluorescence intensity (FI). This figure was adapted from Sarkar et al. 
(2008)81; 82 
 
Although a weak correlation between functional expression levels and higher 
thermostability was observed during directed evolution of certain GPCRs82, extensive screening  
and mutant recombination efforts were still necessary to identify receptor variants with very 
high thermostabilities that were suitable for structure determination83; 84.  Therefore, Daniel J. 
Scott from this laboratory adapted the above-described directed evolution method to specifically 
select for more stable receptors in detergent solution (Figure 1.7)85. The key development of this 
second technology, termed CHESS (Cellular High-througput Encapsulation Solubilization and 
Screening), was to surround E. coli cells after GPCR expression by a semipermeable 
polysaccharide capsule, which allowed solubilization of the cells by harsh detergents without 
loss of the genotype-phenotype linkage. Labelling of the capsules with a fluorescent ligand and 
the FACS-based selection pressure could subsequently be applied analogously to the method 
described above. Since the capsules cannot be cultivated like cells after enrichment, the genes 
encoding for the most stable receptor variants were amplified by PCR after FACS sorting. 
Subsequently, they were ligated to expression vectors before the next “generation” of directed 
evolution was started. 
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Figure 1.7   Directed evolution method for the generation of stable GPCR variants in harsh short-chain 
detergents. The detergent resistant capsule of E. coli is depicted in green. The encapsulation method takes 
advantage of the negative surface charge of E. coli, which aids in the deposition of positively charged 
chitosan (poly-D-glucosamine) and subsequently of a layer of negatively charged alginate. The pore size of 
the semipermeable capsule can be controlled by the number of deposited layers of alternative charges and 
it is fine-tuned to be permeable for detergent monomers and ligands and impermeable for solubilized 
receptors and plasmids. The figure was adapted from Sarkar et al. (2008)81; 85. 
 
Similar to the alanine-scanning approach, a limitation of directed evolution is the 
requirement for an MP ligand as a functional readout. Ligands have to be labelled fluorescently 
and they should be sufficiently small to diffuse into the periplasmic space or through the pores 
of the capsules. They have to be soluble in water and should exhibit little non-specific binding to 
cellular components or to the capsules. These requirements limit the current applicability of 
directed evolution to receptors with suitable ligands, suggesting that further developments are 
needed to increase the target range of this strategy and to make it generally applicable for all 
MPs. 
In spite of this limitation, it is apparent that directed evolution bears an enormous 
potential for the efficient generation of useful MP variants, since it does not rely on manual trial-
and-error procedures. Unlike homology screens or alanine-scans, this concept requires no 
handling of single MP variants – neither at the level of molecular cloning, nor at the phenotypic 
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characterization stage – as it relies on random mutagenesis and on the fully automated FACS 
procedure with two orders of magnitude higher throughput than 384-well plates.  
Compared to alanine-scanning, which is restricted to the substitution of one type of amino 
acid, directed evolution benefits from the possibility to introduce the entire range of natural 
amino acids during random mutagenesis. This may explain why significantly higher 
thermostabilities of evolved variants were measured than for the best alanine mutants in the 
case of NTR1 (the only GPCR, where both methods were applied)86. 
Compared to homology screens, an advantage of directed evolution is that it does not 
require a pre-existing diversity of life, which was generated by variable selections and genetic 
drift over billions of years. It relies on a controlled selection pressure that can direct the 
evolution of specific characteristics within weeks. As a result, improved MP variants can be 
generated while retaining a very high sequence identity to the protein of interest. Thus, in 
contrast to most crystallized prokaryotic homologs of human proteins, evolved MPs can in 
principle be used to obtain structural data of direct pharmacological relevance. 
 
1.4.  Goal of this work 
Directed evolution for high functional expression levels in E. coli was published by Sarkar 
et al.81 before the start of my dissertation in June 2009. In this study, NTR1 – a GPCR that had 
never been crystallized in spite of decades of crystallographic efforts87-92 – was used as a proof of 
principle case to demonstrate the feasibility of the evolutionary method. Sarkar et al. obtained 
an NTR1 variant, termed D03, which exhibited approximately 10-fold increased functional 
expression levels in E. coli and more than 98 % sequence identity to the wild-type GPCR of 
interest. 
My aim was to solve a high-resolution crystal structure of this evolved NTR1 variant in 
complex with its natural agonist neurotensin. This had several reasons: First, a structure would 
prove that directed evolution can be useful for GPCR structural biology and potentially also for 
other MP targets. Second, E. coli would be introduced or established as a valuable host for 
functional GPCR overexpression at large quantities, which would pave the way for various NMR 
experiments tackling receptor dynamics. This had previously not been feasible for 
perdeuterated and functionally produced GPCRs from E. coli. And third, in 2009 only four unique 
GPCR structures were available – mostly showing receptors in inactive conformations. NTR1 
bound to an agonist (neurotensin) would give novel insights about GPCR activation and since no 
peptide-binding GPCR structures were available, a structure of this type would shed light on new 
aspects of an entire subfamily of class A GPCRs. 
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1.5.  Initial progress 
1.5.1.  Previous work 
The group of Reinhard Grisshammer at the NIH membrane protein structure and function 
unit in Rockville (MD, USA) attempted to solve the structure of NTR1 since 1993 and published 
expression trials in E. coli and several improvements of a purification procedure49; 50; 51; 52; 53; 54. 
Their NTR1 isolation method relies on extraction from whole cells using a mixture of 
DDM/CHAPS/CHS, on immobilized metal-chelate affinity chromatography (IMAC) and 
subsequently, on a ligand-column that is based on the interaction of streptavidin and 
biotinylated neurotensin. A postdoctoral fellow and a PhD student tried to implement these 
purification principles in our group and started crystallization trials using the evolved variant 
D03. In spite of my extensive analysis of their laboratory documentations (they left the group 
before the start of my work), I was not able to find clear evidence for successful large-scale 
expression experiments or for reasonably pure GPCR samples and monodisperse size-exclusion 
chromatography (SEC) runs.  
 
1.5.2.   Implementation of the “Grisshammer protocol” 
I started off by implementing and improving the efficiency of the individual steps of the 
Grisshammer protocol systematically one by one for the D03 variant. My initial experiments 
focused on expression optimization using different cultivation temperatures, E. coli strains and 
induction conditions. E. coli BL21 Tuner cells cultivated at 29 °C showed higher functional 
expression levels per cell in radioligand-binding assays compared to E. coli DH5α cultivated at 
20 °C (Grisshammer protocol). In addition, E. coli BL21 Tuner cells grew reproducibly to 
significantly higher cell densities under expression conditions. This lead to more than 2-fold 
increased functional expression using this alternative strain, which corresponded to a total of 
approximately 1.6 mg of active D03 per liter of culture, as estimated by radioligand-binding 
measurements.  
Subsequently, western blots, radioligand-binding assays and SDS-PAGE analyses were 
used to monitor solubilization and purification efficiencies (a selection of results are shown in 
Figure 1.8). The only adaption of the Grisshammer protocol in these trials was the replacement 
of the streptavidin matrix by a monomeric avidin resin. This was necessary due to the reduced 
salt sensitivity of D03 in terms of ligand-binding. In the Grisshammer protocol, NTR1-wildtype is 
eluted from the biotinylated neurotensin (immobilized at the streptavidin resin) by high salt 
concentrations. This was not possible for D03 even in the presence of excess NT8-13 (Figure 
1.8C), as ligand-binding appeared to be salt-insensitive. The monomeric avidin resin, which we 
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applied, was shown to display a weaker interaction to biotin than streptavidin, so that 
biotinylated ligands can be eluted using excess biotin93. In contrast to the elution procedure in 
the Grisshammer protocol, which disrupts the GPCR-ligand interaction, we could thus attempt to 
elute the receptor-ligand complex as a whole. 
 
Figure 1.8  D03 purification trials according to the protocol of the Grisshammer group (previously 
developed for wild-type NTR1). A, E. coli expression construct. B, Western blot analysis of a representative 
IMAC purification using an anti-MBP primary antibody. C, SDS-PAGE of key fractions during monomeric 
avidin/biotinylated neurotensin purification (progression from left to right). Note that high salt elution 
using excess neurotensin (El. NT8-13) was not successful, but immobilized D03 could be eluted by 
competition with excess biotin from the monomeric avidin resin (El. Biotin). A major fraction of D03, 
however, remained on the resin, suggesting that it bound non-specifically. 
 
The major problems of the purification trials according to the Grisshammer protocol were 
the time requirements until completion of the procedure (4 days)  and the low yields after the 
final ligand-affinity step (< 0.08 mg per liter E. coli culture). The latter was due to the following 
three reasons: First, in spite of extensive IMAC tests regarding incubation time during binding, 
imidazole concentrations and column materials, it was not possible to isolate a major fraction of 
D03 – a large part of the fusion protein was in the IMAC flow-through (Figure 1.8B is a 
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representative example). The column capacity of the Ni-NTA IMAC resin (QUIAGEN) for the D03 
fusion construct was estimated to be below 0.1 mg/ml. Second, TEV protease cleavage was 
highly inefficient, as stoichiometric amounts and overnight incubation were necessary to 
achieve complete cleavage (Figure 1.8C).  And third, only a small fraction of D03 could be eluted 
from the monomeric avidin beads, independent of the applied biotin concentration or incubation 
time (biotin was usually applied in large excess). The major fraction remained bound to the 
monomeric avidin resin (Figure 1.8C), implying that D03 interacted mostly in a non-specific way 
with the column material, which might have been due to its aggregation tendency. 
1.5.3.  An alternative purification procedure 
Inspired by a generally applicable membrane protein isolation procedure that is 
frequently carried out in the Group of Raimund Dutzler (Institute of Biochemistry University of 
Zurich), it was also attempted to purify D03 from prepared membranes using IMAC, followed by 
“reverse IMAC” after protease cleavage and imidazole removal. The main problems using this 
approach were again a relatively low binding efficiency during the initial IMAC step, the 
inefficient TEV protease cleavage reaction (typically performed with rhinovirus 3C protease in 
the Dutzler group) and loss of most of the D03 in the reverse IMAC step due to column 
interaction (in spite of complete His-tag removal, data not shown). One attempt was made to 
replace the reverse IMAC step by cation exchange chromatography, which resulted in smaller 
losses of D03. However, due to the inefficient binding to the IMAC in the first purification step of 
the protocol, the final yields were still low and the purified proteins appeared to be mostly 
aggregated, as judged by SEC (Figure 1.9). 
 
Figure 1.9  SEC analysis of D03 in 0.1 % (w/v) DDM. This chromatogram was obtained after extraction 
from prepared membranes, followed by the subsequent steps IMAC, TEV protease cleavage and cation 
exchange. The void volume of this column (Superdex 200 10/300 GL) is at an elution volume of 8 ml. 
Monomeric D03 in a DDM micelle would be expected to elute between 12 – 14 ml. SDS-PAGE analysis of 
collected fractions implied that the void peak consists mainly of D03 and to a lesser extent of residual 
fusion proteins (cleaved) and of TEV protease (data not shown). 
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1.5.1.  Conclusions and further strategy development 
The various observations of non-specific binding events, the surprisingly low capacity of 
IMAC resins and the poor running behavior on S200 were consistent with D03 being an unstable 
protein. Radioligand-binding measurements of purified D03 in DDM further indicated a half-life 
of less than 10 h at 4 °C, which was clearly too short for crystallographic purposes. As the ligand 
column was the last step of the protocol and since it took place more than 48 hours after 
solubilization, this finding explained well, why only a small fraction of the functionally expressed 
receptor could be eluted as a ligand-bound complex from the monomeric avidin resin. 
The previously obtained structures of rhodopsin, β1-adrenergic receptor, β2-adrenergic 
receptor, A2A adenosine receptor were all determined in ligand-bound states, which likely 
reflected the fact that ligand binding frequently increases the stability of its binding protein. 
Considering this, it was investigated whether ligand-binding could potentially prevent the fast 
decay of D03 activity in solution, which was indeed the case (Figure 1.10) 
 
Figure 1.10  Stability measurement of purified protein in solution (10 mM HEPES pH8, 200 mM NaCl, 300 
mM imidazole, 0.1 % (w/v) DDM). 1 ml SEC columns were used to separate bound radioligand (void) from 
free (retained within the column) in a table-top centrifuge. The solid line represents specific ligand-
binding activity after incubation in the absence of 3H-neurotensin, whereas the dashed line was obtained 
after incubation periods in its presence. 
In summary, my initial experiments generated a body of evidence that consolidated 
previous observations on D0381, but importantly, they also outlined new core problems  for 
structure determination on evolved NTR1 variants and an improvement in this regard: First, it 
was clear that functional expression levels (1.6 mg/L of E. coli culture) were no longer limiting 
crystallographic structure determination attempts. Second, unlike previously stated81, the fast 
decay of ligand-binding activity in solution suggested that D03 may not be of sufficient stability 
for crystallization. Third, the stability in DDM could be improved significantly by ligand binding. 
And fourth, since the ligand-affinity column is implemented as a last step in the Grisshammer 
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protocol and because of the long processing time, the procedure appeared to be suboptimal for 
crystallization. 
An extensive literature research further showed that significantly harsher detergents than 
DDM are needed to be applied for GPCRs, if structure determination in the absence of T4 
lysozyme (by vapor diffusion) is attempted (e.g. OG, NG or HEGA10). Based on the sum of these 
findings, a new tripartite strategy was followed: 
1.  I focused on the development of a more efficient purification strategy, which is 
based on a ligand column as the initial isolation step. A procedure of this type 
would profit from an early stabilization effect of the ligand, but at the same time, 
it would still allow separation of native and unfolded receptors. In addition, I 
generated various NTR1 constructs with alternative truncations for 
crystallographic purposes. 
2.  Karola Schlinkmann from our group applied directed evolution for functional 
expression and subsequently, thermostability screening and recombination 
procedures to identify mutants with higher thermostability84; 86. The variant 
TM86V, which was crystallized in the course of my work was obtained as a result 
of her progress. 
3.  Daniel James Scott from our group used the opportunity of lacking stability to 
develop and apply CHESS as described in section 1.3.4. 85. The variants OGG7 and 
HTGH4 that were crystallized in the course of my work were obtained as a result 
of his progress. 
 
1.6.  Thesis outline 
My own work included functional assays on NTR1 mutants, but mostly purification 
optimization, crystallization and structure determination of evolved variants. Chapter 2 of this 
thesis is a manuscript focusing on a novel purification strategy in the GPCR field that was 
developed in the course of this work (to be submitted). The described purification strategy was 
the basis for all successful NTR1 structure determination attempts in our research group. 
Chapter 3 is a PNAS article that summarizes our structural data on the 3 crystallized NTR1 
variants and its implications for our understanding GPCR function. Chapter 4 is meant to be a 
brief outlook towards studying dynamic aspects of GPCR signaling by means of our well-behaved 
model proteins. It comprises initial results from solution-state NMR, which were obtained in 
collaboration with Dr. Franz Hagn (Wagner group, Harvard Medical School). 
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2.2.  Abstract 
G protein-coupled receptors (GPCRs) are key players of cell signaling, thus representing 
important drug targets for the treatment of human diseases. Since inherent difficulties in 
receptor production and handling have precluded the application of many in vitro experiments, 
major questions about GPCR mechanisms and dynamics remain elusive to date. We recently 
used directed evolution in E. coli on neurotensin receptor 1 (NTR1) for the generation of GPCR 
variants with greatly elevated functional expression levels and with excellent stability in 
detergent micelles. In this work we outline a highly efficient purification method for our evolved 
receptor variants, which is based on the application of an inexpensive, disposable high-affinity 
ligand column as the initial purification step. The ligand resin allows isolation of correctly folded 
GPCR variants directly from whole E. coli cell lysates at the scale of 10 mg and it permits 
preparations of agonist- and antagonist-bound receptor samples. The purification principle 
presented here was key to the first structures of signaling-active NTR1 variants. Since E. coli is 
uniquely suitable for the production of fully deuterated proteins, our method provides the basis 
for an array of NMR experiments that were not feasible for GPCRs to date, but which will shed 
light on novel aspects of receptor function and dynamics. 
Keywords: Membrane protein, directed evolution, G protein-coupled receptor, protein stability, 
ligand affinity purification 
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2.3.  Introduction 
The neurotensin receptor 1 (NTR1) is a GPCR that is expressed in the human intestine and 
in the nervous system [1]. It binds to the 13-amino-acid peptide neurotensin (NT), which plays 
important roles in hypothermia, antinociception, the pathogenesis of Parkinson’s disease, 
schizophrenia and lung cancer progression [2-5]. Upon NT binding, the receptor triggers 
GDP/GTP exchange within heterotrimeric G proteins, which leads to downstream stimulation of 
phospholipase C and adenylyl cyclase that produce second messengers in the cytosol [6, 7]. Due 
to a lack of experiments tackling NTR1 dynamics, little is known about the signal-transduction 
mechanism across the plasma membrane, but insights of this type would improve our 
understanding of the receptor in its signaling network and facilitate drug development. 
Like many other GPCRs, NTR1 has been studied extensively in the contexts of native 
membranes and in vivo [8-10]. Investigations in vitro, on the other hand, were largely precluded 
due to receptor instability in detergent solution. Recently, this problem was approached by 
alanine-scanning mutagenesis, which generated a thermostable, but signaling-deficient NTR1 
variant that was fused to T4 lysozyme for crystallization in a mild lipidic cubic phase 
environment [11]. In parallel, we have applied directed evolution technologies that generated 
NTR1 variants with significantly higher stabilities [12-15]. Several of the evolved NTR1 variants 
could be crystallized in harsh detergent environments by standard vapor diffusion experiments, 
and high-resolution structures were determined in the NT-bound state, thus confirming the 
structural integrity of the evolved variants [16]. One of the crystallized constructs, termed 
TM86V-ΔIC3A, was functionally characterized. It was signaling-active, it bound agonist and 
antagonist with high affinities and it exhibited residual desensitizing internalization behavior 
typical for a GPCR. 
The evolved NTR1 variants may serve as useful model GPCRs for future biophysical 
studies. They exhibit up to 60 fold improved functional expression levels in E. coli and thus 
benefit from several advantages of the prokaryotic expression host, such as quick genetic 
modification strategies, growth to high cell densities, fast doubling times, inexpensive media, 
absence of glycosylation and robust handling. Furthermore, prokaryotic production now allows 
to fully deuterate large quantities of functionally expressed NTR1 variants, which will improve 
signal-to-noise ratios in many NMR experiments [17] that were previously not feasible with 
natively produced GPCRs. 
In this work, we describe a highly efficient method for the isolation of evolved NTR1 
variants directly from whole E. coli cell extracts, which is based on ligand binding and thus 
allows the enrichment of correctly folded receptors only. In contrast to previously documented 
NTR1 preparations from E. coli [18-20], the strategy presented here enabled us to purify within 
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significantly shorter time larger quantities of receptor samples with improved homogeneity, 
even in very harsh short-chain glucosidic detergents. The method was key to the crystallization 
of several agonist-bound NTR1 variants in signaling-competent states [16], and we show that 
the purification concept is also applicable for the isolation of large quantities of functional 
receptors bound to antagonist. 
2.4.  Materials and Methods 
2.4.1.  Materials 
Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from Biosolve. All detergents 
were obtained from Affymetrix. Cholesteryl hemisuccinate tris salt (CHS) and lysozyme were 
purchased from Sigma. Empty PD10 columns, NHS-activated Sepharose, SP Sepharose, 
Superdex-200 10/300 and HighLoad 16/600 Superdex-200 were obtained from GE Healthcare. 
Complete EDTA-free protease inhibitor tablets and DNase I were purchased from Roche. The 
neurotensin receptor 1 (NTR1) antagonist SR142948 was obtained from Axon Medchem. 
Amicon Ultra concentrators were purchased from Millipore. Ampicillin was obtained from 
AppliChem, Ni-NTA was purchased from Qiagen. Micro Bio-spin columns were obtained from 
Biorad. 
2.4.2.  Construct design 
The NT ligand constructs for NHS-activated Sepharose coupling were expressed using a 
pAT223-derived vector (GenBank accession number AY327138) for IPTG-inducible expression. 
The open reading frame encoded an N-terminally Avi-tagged protein D (pD), which is at its C-
terminus connected to an internal hexa-histidine tag, followed by the linker GS(GGGS)4, a human 
rhinovirus (HRV) 3C protease site (LEVLFQGP), two glycines and amino acids 8-13 (RRPYIL) of 
human/rat NT (QLYENKPRRPYIL). This construct (Fig. 2.1) is referred to as pD-NT [16]. The 
mutant pD-NT constructs encoded alanine substitutions in the C-terminal NT8-13 moiety (R8A, 
R9A, P10A, Y11A, I12A, L13A or I12A+L13A) and the HRV 3C protease site was replaced by the 
non-cleavable linker GGGGSGG. 
All NTR1 variants were subcloned into a pBR322-derived vector, which was originally 
obtained as a kind gift from R. Grisshammer (National Institute of Neurological Disorders and 
Stroke, National Institutes of Health, Rockville USA) [12, 21]. The open reading frame of the 
modified vector encoded an N-terminal maltose-binding protein (MBP, including its periplasmic 
signal sequence) linked via a GSNN linker, hexa-histidine and an HRV 3C protease site 
(LEVLFQGP) to residue G50 of the receptor (sequential NTR1 numbering). The NTR1 variants 
were C-terminally truncated at G390 and linked via a HRV 3C protease site, a penta-asparagine 
linker, and a di-glycineserine linker to thioredoxin A (TrxA), which is followed by a deca-
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histidine tag. Amino acids V280-I295 of the intracellular loop 3 were deleted in all illustrated 
purification procedures involving NTR1 variants OGG7 and HTGH4 (Fig. 2.4 C, front and middle) 
and in the TM86V-agonist complex purification in n-octyl-β-D-glucopyranoside (OG) (Fig. 2.4 B). 
For all described TM86V purifications in n-nonyl-β-D-glucopyranoside (NG), amino acids E273-
T290 of the intracellular loop 3 were deleted (Fig. 2.4 C, back and Fig. 2.6). 
2.4.3.  Expression and purification of pD-NT contructs 
Five ml 2×YT medium containing 1 % (w/v) glucose and 50 µg/ml ampicillin was 
inoculated with a single colony of E. coli BL21 harboring the pD-NT expression plasmid. The 
culture was incubated for 8 h at 37°C. Subsequently, 1 ml of this culture was used to inoculate 1 
L pre-culture (2×YT, 1 % (w/v) glucose, 50 µg/ml ampicillin), which was grown overnight at 
37°C to saturation. A 50 L fermenter (Bioengineering), containing 2×YT medium, 0.6% (w/v) 
glucose, and 50 μg/ml ampicillin, was inoculated to OD600 0.05 and grown to an OD600 of 1.5 at 
37°C, followed by induction with 1 mM IPTG, and growth was continued for 3 – 4 hours. The pH 
was kept constant at 6.5. Cells were harvested using a continuous-flow centrifuge. 
All pD-NT constructs were purified at 4°C via the internal histidine-tag using immobilized 
metal-ion affinity chromatography (IMAC). A 100 g aliquot of the cell pellet (corresponding to 
less than a fifth of a fermenter yield) was resuspended by a Yellow Line DI 25 basic homogenizer 
(IKA) in 300 ml lysis buffer containing 50 mM HEPES, pH 8, 500 mM NaCl, 25 mM imidazole, pH 
8, 30 complete EDTA-free protease inhibitor tablets, a spatula tip of DNaseI and 5 mM MgCl2. 
The cells were lysed by one processing round of a T1.1 cell disrupter (Constant Systems) at 
35,000 psi. Pelleting of cell debris was carried out in a Sorvall Evolution RC centrifuge at 30,000 
g using an SLA1500 rotor (tilted neck 250 ml tubes, SORVALL). The supernatant was loaded 
onto 12 × 4 ml pre-equilibrated Ni-NTA resin in empty PD10 columns (bench-top gravity flow). 
The resin was washed using a Cerex SPE Processor pressure-flow device (Varian) by 10 column 
volumes equilibration buffer (25 mM HEPES pH 8, 500 mM NaCl, 25 mM imidazole, pH 8) and 
subsequently by 10 column volumes carbonate buffer (0.2 M NaHCO3 pH 8.3, 500 mM NaCl, 5 
mM imidazole, pH 8). The elution buffer contained 0.2 M NaHCO3, pH 8.3, 500 mM NaCl and 300 
mM imidazole, pH 8. The eluted protein was concentrated to approximately 20 mg/ml using 4 
Amicon-15 ultra concentrators and subsequently it was dialyzed (6,000 – 8,000 Da cutoff) 
against 3 × 1 L coupling buffer containing 0.2 M NaHCO3, pH 8.3, and 500 mM NaCl (one dialysis 
step was performed overnight). The purified pD-NT constructs were diluted to 12 mg/ml with 
coupling buffer and they were frozen in liquid N2 in 12.5 ml aliquots (typically 5 – 6 aliquots 
from one purification) and stored at -80°C. 
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2.4.4.  Coupling of pD-NT constructs to NHS-activated Sepharose 
In one coupling reaction 25 ml of purified pD-NT construct at 12 mg/ml was coupled to 50 
ml slurry of NHS-activated Sepharose (2 × 25 ml; #17-0906-01, GE-Healthcare). Briefly, the NHS-
resin was divided equally into 10 empty PD10 columns, which were mounted to a Cerex SPE 
Processor pressure-flow device (Varian) at room temperature. The isopropanol-containing 
storage solution was drained and each column was washed with 60 ml of ice-cold 1 mM HCl. The 
columns were closed at the bottom prior to the addition of 2.5 ml of purified pD-NT per column. 
The resin was resuspended immediately in the pD-NT solution, followed by incubation for 2 h on 
a roller mixer (Stuart). The columns were subsequently drained and the coupling efficiency was 
analyzed by Bradford assays or by SDS-PAGE analysis of the drained solution (Fig. 2.2). The 
unreacted NHS-groups were quenched by washing each column with 10 ml of 100 mM Tris-HCl, 
pH 8.5 and further by resuspending the resin in 5 ml of 100 mM Tris-HCl, pH 8.5 (incubation on 
a roller mixer (Stuart) for 2 h at room temperature). Subsequently, 3 washing cycles using 12 ml 
of 100 mM sodium acetate, pH 4.5, 500 mM NaCl and 12 ml of 100 mM Tris-HCl, pH 8.5 per 
column and cycle were performed. To completely inactivate putatively co-purified proteases 
that may prevent long-term storage of the resin, each column was washed with 24 ml of 6 M 
GdmCl. Each column was then washed with 24 ml H2O and with 16 ml of 20 % ethanol. The resin 
from all columns was collected and stored in 20 % ethanol as 50 ml slurry containing 25 ml pD-
NT Sepharose (bed volume). Performing the coupling reaction on multiple benchtop-systems 
greatly facilitated the resuspension steps, as compared to the usage of one large column. 
2.4.5.  Large-scale expression and purification of agonist-bound NTR1 variants 
Fermenter runs with E. coli BL21 Tuner cells harboring the NTR1 expression plasmids 
were performed as previously described [16]. In a typical purification, 50 g of cell pellet 
(corresponding to a 7% aliquot of a fermenter run) were resuspended by a Yellow Line DI 25 
basic homogenizer (IKA) in 100 mL solubilization buffer containing 100 mM HEPES, pH 8, 20 % 
(v/v) glycerol and 400 mM NaCl. All subsequent steps were carried out at 4°C. 0.5 mL of 1 M 
MgCl2, a spatula tip of DNase I, 200 mg lysozyme, 20 mL of a solution of 6 % (w/v) 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane sulfonate (CHAPS) / 1.2 % (w/v) CHS, and 34 
mL of 10 % (w/v) n-decyl-β-D-maltopyranoside (DM) were added to the resuspended cells 
while stirring. The mixture was incubated while stirring for 15 min. Sonication was performed 
for 30 min in an ice-water bath using a Sonifier 250 (Branson) at a duty cycle of 30 %, output 5, 
with sonication tip extension from Heinemann (13 mm) and a stirring bar at 250 rpm within the 
extraction mixture. Subsequently, 4 mL of 0.5 M EDTA was added to the extraction mixture, 
followed by another 30 min incubation while stirring. The suspension was transferred to one 
250 ml tilted neck centrifugation tube (SORVALL) and centrifuged for 30 min at 15,000 rpm 
(SLA 1500 rotor). The supernatant was transferred to a 250 ml glass bottle and mixed with 5 mL 
A CLEAVABLE LIGAND COLUMN FOR THE ISOLATION OF FUNCTIONAL NTR1 37  
 
slurry pD-NT-ligand resin that was pre-equilibrated in NT wash buffer 1 (25 mM HEPES, pH 8, 
10 % (v/v) glycerol, 600 mM NaCl, and 0.5 % (w/v) DM). The NT binding reaction was incubated 
on a roller mixer (Stuart) overnight. Subsequently, the mixture was centrifuged at 400 g for 10 
min, and 90 % of the supernatant was decanted.  
Using the remaining supernatant, the pelleted pD-NT resin was transferred to an empty 
PD10 column, and it was washed on a bench top in a cold room on a Cerex SPE Processor 
pressure-flow device (Varian) with 75 mL of wash buffer 1. The resin was subsequently washed 
by 40 mL of NT wash buffer 2 containing 25 mM HEPES, pH 7, 10 % (v/v) glycerol, 150 mM NaCl, 
4 mM DTT and 0.4 % (w/v) NG. In the NT wash buffer 2 and in all subsequent purification 
buffers, various detergents at concentrations depending on their particular critical micelle 
concentration were tested for individual in vitro applications. For simplicity, only the one 
detergent (NG) is mentioned in this description (see Fig. S2.7 for a summary of alternatively 
applied detergents). The resin was resuspended in a small volume of wash buffer 2 within the 
column, containing 0.7 mg of HRV 3C protease (produced in house), followed by incubation for 2 
h. The eluted protein (10 mL) was diluted three-fold with SP binding buffer, containing 10 mM 
HEPES, pH 7, 10 % (v/v) glycerol, 4 mM DTT, and 0.3% (w/v) NG, and it was subjected to 
another PD10 column (gravity flow) containing 5 mL SP Sepharose (bed volume), which had 
been pre-equilibrated with SP binding buffer. The SP resin was washed with 10 mL SP binding 
buffer, followed by 25 mL SP wash buffer containing 10 mM HEPES, pH 7.7, 10 % (v/v) glycerol, 
35 mM NaCl, 4 mM DTT, and 0.3 % (w/v) NG, followed by another 3 mL SP binding buffer. 
Elution was carried out by ∼15 mL SP elution buffer containing 10 mM HEPES, pH 7, 10 % (v/v) 
glycerol, 350 mM NaCl, 4 mM DTT, 0.3 % (w/v) NG and 500 nM NT1 (GPGGRRPYIL). NT1 
corresponds to the C-terminal part of the fusion protein cut off by HRV 3C protease, i.e., the 
remaining HRV 3C protease site (GP), two linker residues (GG) and the NTR1 binding-epitope of 
NT, which is NT8-13 (RRPYIL). 
Whenever quantitative size exclusion chromatographic analyses were performed, the 
NTR1 variants were concentrated by an Amicon-15 Ultra concentrator with 50 kDa cutoff to less 
than 500 μL (this cutoff was suitable for all tested detergents). The concentrate was transferred 
to an Eppendorf tube and centrifuged in a table-top centrifuge for 10 min at 10,000 g. The 
supernatant was loaded on a Superdex-200 10/300 column that was pre-equilibrated with 
running buffer containing 10 mM HEPES, pH 8.0, 150 mM NaCl, 4 mM DTT, 0.28 % (w/v) NG, 
and 100 nM NT1. 
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2.4.6.  Identification of mutant pD-NT columns for antagonist-bound receptor 
purifications 
The pD-NT constructs carrying various mutations in the NT moiety were expressed at the 
scale of 1 L E. coli cultures in 2×YT (0.2 % (w/v) glucose, 100 µg/ml ampicillin). After 
inoculation to OD600 of 0.05 from a saturated pre-culture, the cells were grown at 37°C and they 
were induced by 1 mM IPTG for 4 h after reaching OD600 of 0.6. The cells were harvested by 
centrifugation and they were resuspended in 25 ml lysis buffer (50 mM HEPES, pH 8, 500 mM 
NaCl, 25 mM imidazole pH 8, two tablets of complete protease inhibitor cocktail). The mutant 
pD-NT proteins were purified and coupled to NHS-activated Sepharose analogously to the 
above-mentioned protocol for the wild-type NT ligand construct, albeit at 10-fold smaller scale 
(using 5 ml slurry ligand column). 
Small-scale TM86V purification tests were performed in parallel as follows: For all mutant 
pD-NT constructs (and wild-type pD-NT as control) 1 ml slurry ligand resin (equilibrated in NT 
wash buffer 1) was transferred to a 50 ml Falcon tube. Twenty ml of solubilized TM86V 
(corresponding approximately to one tenth of the preparation from 50 g of E. coli cells as 
described above) was applied to each resin and the mixtures were incubated overnight at 4°C. 
The pD-NT resins were subsequently pelleted at 400 g in a swinging-bucket rotor and 
transferred to empty Micro Bio-spin columns. Each resin was washed by 10 ml NT wash buffer A 
(25 mM HEPES, pH 8, 600 mM NaCl, 10 % (v/v) glycerol, 0.5 % (w/v) DM), followed by 3 ml NT 
wash buffer B (25 mM HEPES, pH 7, 2 mM DTT, 150 mM NaCl, 10 % (v/v) glycerol, 0.5 % (w/v) 
DM). At this stage the pD-NT resin samples corresponding to Figure 2.5 A (see below) were 
collected. Subsequently, 500 ul of antagonist elution buffer (10 mM HEPES, pH 7, 2 mM DTT, 150 
mM NaCl, 10 % (v/v) glycerol, 0.5 % (w/v) DM, 5 mM SR142948) was added to each resin, 
followed by incubation of the mixture for 30 min on a roller mixer (Stuart). The columns were 
subsequently drained (elution: samples C in Figure 2.5) and the resins were washed with 
another 2 ml of antagonist elution buffer. Further samples were collected from the washed 
resins after elution (samples B in Figure 2.5). 
2.4.7.  Large-Scale antagonist-bound TM86V purification 
Solubilization of TM86V, receptor immobilization at the pD-NT-P10A resin and washing of 
the resin by NT wash buffer 1 was performed analogously to the purification protocol for the 
NT-bound NTR1 variants. The ligand resin was subsequently washed by 30 ml of pD-NT-P10A 
wash buffer 2 (25 mM HEPES, pH 7, 10 % (v/v) glycerol, 150 mM NaCl, 4 mM DTT and 0.5 % 
(w/v) DM). One bed volume of antagonist elution buffer (21 mM HEPES, pH 7, 8.5 % glycerol, 
128 mM NaCl, 4.3 mM antagonist, 0.85 % DM) and 500 ul of HRV 3C protease (0.7 mg) was 
added to the washed resin. The column was closed, the resin was resuspended and the mixture 
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was incubated for 2 h on a roller mixer (Stuart). Note that the antagonist stock solution for the 
elution buffer contained 5 mM SR142948 in 1 % (w/v) DM (the antagonist was insoluble in H2O 
above 1 mM). The column was subsequently drained and further eluted by pD-NT-P10A wash 
buffer 2 to give a total of 10 ml elution. Subsequently, 1 ml of 10 % (w/v) NG was added to the 
eluted antagonist-bound TM86V and the solution was diluted by 19 ml SP binding buffer (10 mM 
HEPES, pH 7, 10 % (v/v) glycerol, 4 mM DTT, 0.3% (w/v) NG). All subsequent steps were 
performed analogously to the purification protocol for agonist-bound NTR1 variants (exception: 
all buffers contained 300 nM antagonist and NT1 was omitted). 
2.5.  Results and Discussion 
2.5.1.  Purification strategy and ligand column design 
Many GPCR purification protocols rely on ligand-affinity chromatography to separate 
functional from non-functional protein. At the same time, ligand-binding usually increases 
receptor stability [15, 22-26]. Therefore, it is apparent that a ligand-affinity column would in 
principle be most effectively applied as the initial purification step in a protocol, since this would 
combine the benefits of an activity-based separation with an early stabilization.  
Moreover, many GPCR ligands exhibit nanomolar affinities, hence significantly stronger 
interactions than standard histidine tags display towards nitrilotriacetic acid-immobilized nickel 
ions, which have micromolar affinity [27]. This can be an additional advantage during an initial 
purification step, particularly in the frequent case of low expression levels, when large amounts 
of membrane need to be solubilized and a big volume of the extraction mixture causes dilute 
GPCR concentrations and high quantities of competing impurities. 
However, a tight-binding ligand would normally require a harsh elution step from the 
affinity column. This would jeopardize receptor integrity, since the receptor might denature 
again, and be no longer saturated with ligand, potentially eliminating any gain from such an 
affinity column.   
In order to effectively isolate functional NTR1 variants from solubilized E. coli cell lysates, 
we generated a very inexpensive ligand-affinity resin, which allows mild receptor elution by 
cleaving the binary receptor-ligand complex off the column as a whole.  The receptor takes the 
cleaved off ligand along all of the purification and as a result, it is maximally stable during the 
entire procedure. The ligand component consists of the minimal receptor-binding NT epitope 
(amino acids 8-13) fused to a fragment of protein D from phage lambda (pD) (Fig 2.1). pD is C-
terminally connected to NT8-13 via a long and flexible linker, which encodes an HRV 3C 
protease cleavage site in close proximity to NT. Neither the linker nor NT consist of lysine 
residues. The construct can thus be coupled to NHS-activated Sepharose specifically via pD, 
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which contains 5 lysines and the free N-terminal amino group – leaving NT fully accessible for 
receptor binding and for proteolytic elution.  
 
 
Figure 2.1  Scheme of the NTR1 ligand-affinity Sepharose resin. pD-NT contains an internal His-tag 
allowing its own purification in large quantities via IMAC. The ligand construct can be coupled to NHS-
activated Sepharose specifically via the pD domain, as this part contains all the primary amines encoded in 
the construct (all the lysines and the N-terminus). The long and flexible linker between pD and the C-
terminal NT8-13 (the minimal receptor-binding epitope of NT) allows maximal accessibility of the GPCR 
ligand. A 3C protease site in close proximity to NT8-13 permits quantitative elution of bound, functional 
NTR1 variants in complex with the agonist by proteolytic cleavage 
 
2.5.2.  Ligand production and coupling efficiency 
Fusing the NTR1 ligand to the carrier protein pD was expected to have two beneficial 
effects on the ligand column production: First, N-terminal pD fusions were previously described 
to enhance expression levels of soluble proteins significantly in E. coli [28], thus permitting 
ligand production at large quantities. Second, peptides, such as the NT ligand, are frequently 
degradation-prone, when overexpressed by themselves in E. coli and the linkage to a folded 
domain was expected to minimize this problem. This is far more economical than using a 
synthetic peptide. Up to 100 mg pD-NT could be expressed per liter of E. coli culture and 700 - 
900 mg were typically obtained per purification run, using standard bench-top IMAC procedures 
(Fig 2.2, lane 1). 
The IMAC-purified pD-NT appeared to be pure on SDS-PAGE. However, it was initially not 
possible to achieve high coupling efficiencies to the NHS-activated Sepharose (initial yields: 40 – 
70%). We suspected that small molecules containing primary amines might co-purify with pD-
NT to some extent, and that these potential contaminants act as competitors in the coupling 
reaction. In order to prevent this, we introduced a dialysis step after the IMAC, which indeed 
improved the coupling efficiency to approximately 100% (Fig 2.2). 
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In a typical coupling reaction, 12 mg pD-NT was immobilized per milliliter of NHS-
Sepharose bed volume, corresponding to a theoretical column capacity of 35 mg/ml for full-
length NTR1. Ligand expression (in a fermenter), purification of a small fraction of the expressed 
ligand and NHS-coupling of less than half of the purified pD-NT (350 mg) required typically less 
than 3 days and yielded 25 ml ligand resin (bed volume), which was suitable for more than 10 
large-scale GPCR purifications. 
 
 
Figure 2.2  Analysis of the purification outcome and of the coupling efficiency of 
the ligand construct (pD-NT) to NHS-activated Sepharose. pD-NT was expressed in 
E. coli. It was purified by IMAC, followed by dialysis for the removal of small 
molecule contaminants containing primary amines, which appeared to act as 
competitors during NHS-coupling. Lane 1 shows the purity of the pD-NT construct 
(MW = 16 kDa) after dialysis, but prior to the coupling to NHS-activated Sepharose. 
Lane 2 represents a fair loading of the same solution after exposure to NHS-
activated Sepharose. The absence of pD-NT in lane 2 indicates a highly efficient 
coupling reaction. 
 
2.5.3.  Large-Scale preparation of functional NTR1 variants 
Extraction of NTR1 variants from whole E. coli cells was performed without prior 
membrane preparation using a mixture of DM, CHAPS and CHS. Subsequently, a small amount of 
ligand-affinity resin (2.5 ml bed volume per 200 ml solubilization reaction, cf. Materials and 
Methods) was applied to efficiently pull down milligram quantities of functional receptor from 
the soluble fraction. The ligand-affinity resin and the bound GPCRs were first washed by a DM-
containing buffer and in a second step by a buffer containing a detergent of choice (bench-top 
column in a cold room). As observed by SDS-PAGE analysis, the receptor purity was close to 
100% after this first purification step (Fig 2.4 A, lane 2 and 3). The subsequent addition of 
catalytic amounts of 3C protease allowed quantitative elution of the NT-bound NTR1 via ligand 
cleavage, and concomitantly of its cleaved fusion proteins MBP and TrxA (Fig 2.4 A, lane 5). The 
fusion proteins and the 3C protease were subsequently separated from the receptors by a 
cation-exchange step using a simple gravity-flow column format (bench-top), and the pure NTR1 
variants were typically analyzed by quantitative SEC (Fig 2.4 B). 
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Figure 2.3  Protocol overview for the large-scale 
preparation of NT-bound NTR1 variants from whole 
E. coli cells. Step 1, ligand-mediated pull-down of 
receptors directly from solubilized E. coli cells and 
washing of the NT-affinity resin in batch. The ligand 
is shown in blue. Various detergents can be applied 
in the wash buffer at this stage, in case a detergent 
exchange is required. Step 2, elution of the agonist-
bound receptors and of the fusion proteins from the 
NT-affinity resin via cleavage at the three 3C 
rhinovirus protease sites (magenta). Step 3, removal 
of the cleaved off fusion proteins by cation-exchange 
chromatography in batch (gravity flow). The purified 
receptor/NT8-13 complexes were routinely analyzed 
by SEC (Fig. 2.4 B and 2.4 C). This procedure is 
completed in less than one working day (including 
analytical or quantitative SEC) and allowed the 
isolation > 10 mg of pure receptor/agonist 
complexes. The ligand-mediated pull-down and the 
gravity-flow format allowed processing of several 
NTR1 variants in parallel. 
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Figure 2.4  Analysis of large-scale purifications of NTR1 variants in the NT-bound state in harsh glucoside 
detergents. (A) SDS-PAGE analysis of a typical purification of TM86V in OG. Lane 1, DM/CHAPS/CHS-
solubilized whole E.coli cells. Lane 2, NT-affinity resin after pull-down and wash with DM-containing 
buffer. Lane 3, NT-affinity resin after detergent exchange to 1% (w/v) OG. Lane 4, second wash of NT-
affinity resin using OG-containing buffer (detergent exchange). Lane 5, elution from NT-affinity resin by 
3C protease. Lane 6, flow-through of cation-exchange column. Lane 7, wash of cation-exchange column. 
Lane 8, elution from cation-exchange column. (B) Quantitative SEC (S200 HiLoad 16/600) after elution 
from the cation-exchange column (lane 8 of the gel) using a buffer containing 1% (w/v) OG. (C) Semi-
quantitative SEC of HTGH4 (front), OGG7 (middle) and TM86V (back) in NG-containing buffer. In these 
cases, the detergent was exchanged to 0.3% (w/v) NG on the NT-affinity resin. The dashed line depicts the 
void volume of the SEC column (S200 10/300 GL). 
 
This purification principle by ligand-mediated immobilization was successfully applied to 
the three evolved NTR1 variants TM86V, OGG7 and HTGH4 [15, 16, 29] (Fig 2.4 C) using several 
different detergents (see Fig. S2.7 for a compilation of other detergents used). Choosing the 
ligand-affinity step for detergent exchange was advantageous for two reasons: First, the column 
format allowed direct and early monitoring of NTR1 integrity in the presence of the new 
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detergent by UV-absorbance measurements in the wash fractions; and second, the NTR1 
variants were expected to be maximally stable at this stage, due to the bound ligand, which 
increased the range of tolerated detergents for these intrinsically stable GPCR variants even 
further [15]. 
A typical purification of TM86V in OG yielded 10 mg of ligand-bound receptor (after SEC), 
which corresponds to 3.6 mg per liter of E. coli culture (Fig. 2.4 B). Purifications of OGG7 yielded 
similar amounts of agonist-bound receptors, whereas the same procedure with HTGH4 resulted 
typically in even higher yields (12 – 16 mg).  
The described purification protocol could be completed within one working day and the 
simplicity of the ligand-mediated pull-down and of the gravity-flow format allowed processing 
of several receptor variants in parallel. 
2.5.4.  Purification of antagonist-bound TM86V 
Given the potential of NTR1 antagonists for medical applications [30, 31], atomic-
resolution structural insights about their binding mode are of high interest. We previously 
demonstrated that the evolved and signaling-active NTR1 variant TM86V binds to the antagonist 
SR142948 with high apparent affinity. TM86V was extensively characterized regarding its 
function and, as it yielded well diffracting crystals in complex with neurotensin, it is a promising 
candidate for the establishment of a purification procedure in complex with SR142948 and for 
subsequent crystallization trials. 
In order to benefit from the ligand-mediated receptor isolation principles, we intended to 
adapt the agonist-based purification protocol in such a way that immobilized TM86V was no 
longer eluted from the pD-NT resin via ligand cleavage, but instead by competition with excess 
antagonist (5 mM SR142948; note, [pD-NT] < 1 µmol / ml resin). Unfortunately, even though 
trace amounts of antagonist-bound TM86V could be eluted using this strategy, the receptor off-
rate from the pD-NT construct appeared to be too slow for quantitative TM86V preparations.  
In order to identify a more suitable ligand, we tested several Sepharose resins in parallel, 
each displaying a different version of pD-NT with alternative mutations in the C-terminal NT. 
The SDS-PAGE analysis of the bound, eluted and non-eluted TM86V fractions implied that the 
pD-NT resins carrying the mutations P10A and I12A exhibit a reasonably reduced affinity that 
allows for efficient receptor binding and antagonist-mediated elution (Fig 2.5).  
We then chose to implement the pD-NT-P10A resin and the antagonist competition step in 
the previously developed large-scale purification protocol (Fig. 2.6 A) – i.e. all other steps were 
performed analogously to the protocol for the receptor/agonist complex isolation described in 
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Fig. 2.3. This purification procedure resulted in monodisperse SEC profiles and yielded typically 
about 3 mg of antagonist-bound TM86V per liter expression culture, thus confirming the results 
of the small-scale ligand column screen and the feasibility of this purification strategy for 
crystallization trials (Fig 2.6 B and 2.6 C). Since the antagonist exhibits a characteristic 
absorbance spectrum in the UV-range, the antagonist-bound state of purified TM86V was 
confirmed spectroscopically (Fig. S2.8).  
It is noteworthy that, in contrast to the protease-mediated pD-NT cleavage for the agonist-
bound purification, elution by antagonist competition does not irreversibly remove the ligand 
from the column. But in order to prevent reproducibility problems and due to the simplicity of 
ligand resin production in large quantities, it is preferred to apply the pD-NT-P10A resin in 
single use as well. 
Figure 2.5  Ligand column screen guiding the 
identification of NT8-13 mutations that allow 
TM86V-binding at lower affinity and thus 
permit elution by competition with excess 
antagonist. Seven different pD-NT variants 
were generated in preparation of this 
experiment and they were coupled to NHS-
activated Sepharose. Each variant encoded 
either a single alanine substitution within 
NT8-13 or the double substitution I12A / 
L13A. The lanes are labeled by the 
substituted NT8-13 amino acids of the 
immobilized pD-NT8-13 constructs. The 
figure is an SDS-PAGE analysis from the first 
step of small-scale TM86V purifications from 
solublilized whole E. coli cells(A) pD-NT 
beads after wash (removal of E. coli 
proteins). (B) pD-NT beads after antagonist-
mediated elution. (C) Elution by excess 
antagonist. The band corresponding to 
TM86V is depicted by an arrow. 
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Figure 2.6  Large-scale preparation of antagonist-bound TM86V by pD-NT-P10A Sepharose. (A) 
Schematic representation of the key step. The ligand-affinity resin exhibits a slightly reduced interaction 
strength with TM86V, due to the mutation P10A (yellow star) in NT8-13 (dark blue). Quantitative elution 
is possible with excess of antagonist (SR142948). Note that no 3C rhinovirus protease site is encoded in 
the pD-NT-P10A construct. This allows simultaneous fusion protein removal and competitive elution 
without co-elution of free NT-P10A. The solubilization step and the removal of the cleaved fusion proteins 
by cation-exchange chromatography (in batch) were carried out as described for the purification of 
agonist-bound receptors. (B) SDS-PAGE analysis of a typical purification of antagonist-bound TM86V. Lane 
1, NT-P10A-affinity resin after pull-down and wash with DM-containing buffer. Lane 2, NT-P10A-affinity 
resin after detergent exchange to 0.3% NG (w/v). Lane 3, NT-P10A-affinity resin after competitive elution. 
Lane 4, elution from NT-P10A-affinity resin by antagonist competition. Lane 5, flow-through of cation-
exchange column. Lane 6, wash of cation-exchange column. Lane 7, elution from cation-exchange column. 
Lane 8, cation-exchange resin after elution. (C) Semi-quantitative SEC (S200 10/300 GL) of the combined 
elution fractions from the cation-exchange column (lane 7 in B). The complete purification was performed 
in 0.3% (w/v) NG after detergent exchange. 
 
2.5.5.  Generalizability of purification principle 
A large number of proteins were reported to exhibit high-affinity interactions with 
peptides [32, 33]. Many of these ligands are devoid of lysines, hence similar economic NHS 
immobilization strategies by means of pD-peptide fusions may be feasible for ligand column 
production. In the case where a peptide-binding protein of interest benefits from ligand-
mediated stabilization, or when efficient removal of aggregates is crucial, comparable 
purification strategies may likely improve the quantity and quality of purified proteins critically. 
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2.6.  Conclusions  
Ligand columns are very rarely used as a first step in large-scale GPCR purifications, in 
spite of their potential advantages, such as ligand-mediated receptor stabilization and high 
affinity interactions resulting in an efficient purification. There are several practical reasons that 
preclude the use of such columns.  
Directly applying the soluble fraction to a ligand column would often prevent the repeated 
usage of the resin, as ligands can be unstable under these conditions (e.g. degraded by co-
purified proteases) or because residual cellular debris leads to incomplete column recovery. The 
use of synthetic ligands can be very expensive and prohibitive for single-use columns. Also, 
harsh elution conditions from a tight-binding column with ensuing receptor denaturation might 
abrogate the effect of having captured active receptor in the first place. 
However, in this work we have overcome these problems for the case of a peptide-binding 
GPCR by developing a high capacity ligand column, from which the receptor-ligand complex can 
be cleaved off. The ligand resin is so efficiently and inexpensively produced that the obtained 
column material is suitable for single use, thus rendering column recovery problems irrelevant. 
The pD-NT Sepharose resins described in this work were the basis for time-efficient and 
highly reproducible receptor purifications directly from whole E. coli cell lysates. The outlined 
method was not only the foundation for the first crystal structures of signaling-active NTR1 
variants expressed in a prokaryote, it will also be key to various novel in vitro studies on these 
receptors. As E. coli is the preferred expression host for isotope-labeled protein production, the 
way is now paved for an array of NMR studies that were not feasible using functionally 
expressed GPCRs to date. Future experiments based on these purification principles will likely 
contribute to an improved understanding of GPCR dynamics and thus facilitate drug 
development. 
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2.8.  Supplementary information 
 
Figure S2.7  Compilation of quantitative SEC runs (S200 10/300 GL) using various detergents. This figure 
may guide future in vitro experiments (e.g. optimization of NMR spectra), as it provides an overview of 
detergent conditions that allow reasonably homogeneous preparations of evolved NTR1 variants. The 
chromatograms represent three different receptor variants, which were purified for various purposes 
(purification optimization, crystallography, NMR, MALS). All shown chromatograms represent purification 
procedures that were carried out using the agonist-complex purification strategy described in the main 
text. The exchange from DM to a detergent of choice was performed on the pD-NT ligand column and the 
detergent was kept constant in all subsequent buffers. Since the illustrated receptor preparations were 
not performed in parallel and on different FPLC systems, no conclusions from small differences in running 
behaviors can be drawn.  
(A, B) Early purification optimization trials on NTR1-C7E02 (precursor of NTR1-TM86V [1]). “X” denotes 
an absorbance peak, which is due to residual amounts of TrxA, as verified by SDS-PAGE (data not shown). 
The cleaved fusion protein was not entirely removed during these purification attempts, due to an 
inefficient wash step on the SP Sepharose column. The inefficiency of TrxA removal resulted from the fact 
that the SP wash buffer was kept at pH 7 here, as the optimal pH of 7.7 (current protocol) was identified 
only at a later time point in process development. (C, D) Large-scale purification of NTR1-TM86V. (E, F) 
Large-scale purification of NTR1-HTGH4. Note that this variant may exhibit a tendency for dimerization 
under these conditions in DDM at high concentrations (shoulder at around 12.5 ml elution volume). NM: 
n-nonyl-β-D-maltopyranoside, OTM: n-octyl-β-D-thiomaltopyranoside, OG: n-octyl-β-D-glucopyranoside, 
DM: n-decyl-β-D-maltopyranoside, OGNG: octyl glucose neopentyl glycol, DDM: n-dodecyl-β-D-
maltopyranoside. 
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Figure S2.8  Absorbance spectra of purified TM86V, antagonist SR142948 and agonist NT1 (GGRRPYIL). 
All spectra were either recorded at 100 μM (SR142948) or scaled to the same concentration using 
estimated extinction coefficients (ProtParam online tool from EXPASY). Note that the spectrum of TM86V 
(apo) was determined by measuring the absorbance of purified NT1-bound TM86V followed by 
subtraction of the NT1 spectrum. The difference in absorbance between TM86V (apo) and SR142848-
bound TM86V corresponds well to the antagonist absorbance, thus clearly confirming that the receptor 
can be purified in the antagonist-bound state using the described protocol. This finding is expected, since 
TM86V can be competed from the pD-NT-P10A column by excess antagonist (Fig 2.6) and also because 
competition efficiency is dependent on the position of the alanine substitution in NT8-13 (Fig 2.5). 
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Discussion and Outlook 
Understanding Conformational Dynamics of  
a Model GPCR – The First Steps 
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4.1.  The potential of crystallized NTR1 variants for GPCR research 
NTR1 is an interesting model for GPCR research, as it signals prototypically via several 
different G proteins (see section 1.2.1) and since numerous ligands are available, i.e. antagonists 
and full, partial and biased agonists1; 2. Moreover, its natural ligand is a soluble peptide, which 
can be altered by simple mutagenesis, thus providing an additional handle for experimental 
manipulations. 
However, like the vast majority of GPCRs, NTR1 is not amenable to research applications 
that require large quantities of stable proteins in solution, which was the main reason for 
evolving alternative receptor variants in our research group. The crystal structures reported 
here provide the first snapshots of a signaling-relevant NTR1 state and they prove that large 
amounts of highly stable and pure GPCR variants can now be obtained from E. coli. The 
crystallized construct TM86VΔIC3* is of particular interest, as it shares many functional 
characteristics with wild-type NTR1, like agonist-/antagonist-binding, Gi protein, GRK and β-
arrestin interactions, as well as high sequence identity. Given its high stability and expression 
levels in E. coli, it is a unique model receptor that can be used to study general aspects of GPCR 
function in future experiments in vitro. 
An additional advantage of TM86V-ΔIC3 is the availability of an extremely large amount of 
mutagenesis data. Karola Schlinkmann from this research group investigated the effect of all 
possible single codon substitution at every amino acid position on functional expression levels†, 
which corresponds to an analysis of approximately 20’000 mutants (also see Chapter 3 Fig. S7)3. 
This body of data is a unique practical guide for the design of future experiments, as it 
complements structural data in unprecedented ways (examples in Figure 4.1) and furthermore, 
it inspires many question about fundamental principles of receptor stability, biogenesis, and 
degradation. NTR1 is to my knowledge the only GPCR, potentially the only protein, where all 
effects on functional expression levels of any single nucleotide or single codon substitution are 
known.  
                                                          
* As described in chapter 3, two versions of TM86VΔIC3 exist (A and B). Both variants show residual signaling 
towards Gi (data not shown for TM86VΔIC3B). Additionally, TM86VΔIC3A was tested for internalization, which 
occurred to some extent. TM86VΔIC3B was not tested in this regard. 
† Investigation carried out using the variant D03, which differs at 3 amino acid positions from TM86V. 
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Figure 4.1  Examples of available sequence statistics in the structural context. The relative frequency of 
each codon after one round of FACS is displayed by blue bars in the diagrams (right). The red line depicts 
the expected frequency in the absence of selection pressure. High bars imply favorable codons for 
elevated functional expression levels at the indicated position and vice versa (see Chapter 3 Fig. S7 and 
Schlinkmann et al. (2012)3 for details). Note that the codon with the highest bar is in each plot an expected 
artifact (wild-type codon), which is due to the pooling of libraries – it is not to be taken into account. A, 
Typical examples from the ligand-binding pocket, illustrating the preservation of the neurotensin-
contacting residues upon directed evolution. B, Examples from the transmembrane region. The side chain 
of the amino acid at position 721.40 points into the membrane space and it is thus selected to be an apolar 
residue. Proline 3667.50 is located far away from the ligand-binding site and hence from the selection 
pressure. Nevertheless, it is the only acceptable amino acid for functional expression at this position, 
suggesting that its helix-destabilizing properties are of crucial structural relevance. Position 1162.53 is an 
example for an unexpected result in terms of amino acids selections. Here, wild-type NTR1 harbors an 
isoleucine, but interestingly, a proline residue would also be allowed in spite of its position in the middle 
of the α-helix. The toleration of a non-wild-type proline is a unique exception among all positions. C, Stop-
codons are counter-selected throughout the GPCR, but their relative frequencies increase directly after 
helix 8. Hence, the presence of the amino acid stretch corresponding to Helix 8 is promoting functional 
expression levels, which might be due to its relevance for the structural integrity of the entire GPCR. 
 
4.2.  NMR 
For the β2-adrenergic and many other receptors, pronounced ligand-dependent structural 
changes are not observed by x-ray crystallography, implying that receptor dynamics are an 
important key to the understanding of signaling mechanisms. Similarly, the structures of 
TM86V-ΔIC3 reported here are at the extracellular side in an active, agonist-bound state, but 
intracellularly, they are clearly exhibiting a prototypic inactive conformation. The crystallized 
constructs can nevertheless activate Gi proteins to some extent, which is consistent with a high 
degree of conformational flexibility or the sampling of multiple inactive or active states that was 
previously reported for other receptors4.  
A number of biophysical studies on dynamics and conformational exchange were reported 
in the case of rhodopsin and for the β2-adrenergic receptor, including NMR and DEER (Double 
electron-electron resonance) spectroscopy4-11. Many of these studies provided strong and direct 
evidence for the existence of alternative TM6 conformations in detergent micelles, which was 
interpreted in the context of crystal structures. One limitation of these approaches was the use 
of chemical probes (e.g. spin-labels for DEER or fluorine / 13C-methyl labels for NMR) at specific 
sites that allowed to monitor changes only at very few engineered spots in the receptor.  
In principle, NMR has, however, the potential to follow alterations in chemical 
environments more globally, if appropriate labeling schemes are applied and given that the 
spectra are of sufficient quality for complete assignments. The latter is particularly challenging 
in the case of GPCRs: large proteins, such as MPs in micelles, exhibit comparably slow molecular 
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tumbling, which causes short transverse relaxation times T2 (reduced spin coherence lifetimes) 
and thus low sensitivity and spectral line broadening12. In order to prevent rapid magnetization 
decays to some extent, soluble proteins are usually perdeuterated (> 98 %) and spectra are 
recorded at elevated temperatures13-17. Both of these strategies are inapplicable in the case of 
the vast majority of GPCRs, as they are unstable and because they cannot be overexpressed in E. 
coli – one of the very few organisms, which would allow full deuteration of proteins. 
As the crystallized NTR1 variants fulfill both of these criteria, they represent promising 
candidates, where complete assignments might be obtainable. This would be a starting point for 
a series of experiments that were not possible on GPCRs so far: First, local changes of chemical 
environments may be observed throughout the entire GPCR upon binding of different ligands. 
Second, it may allow to map the binding sites of further ligands or even to determine ligand-
bound structures, if sufficient intra- and intermolecular NOEs can be observed. Third, it may 
allow to map the binding sites of several different G protein variants and to determine relevant 
structural aspects for downstream receptor specificity. Analogous experiments might be 
possible for GRKs and β-arrestins. And fourth, new insights might be generated on 
conformational dynamics, rate constants can potentially be deduced and the population of 
specific states may be estimated under different conditions. This chapter describes initial 
experiments that were conducted with the aim of assigning backbone resonances of evolved 
NTR1 variants.  
4.2.1.  Expression in minimal medium and purification considerations 
To obtain an initial estimate of expression yields in minimal medium for TM86V-ΔIC3B, a 
number of expression conditions in shake flasks were tested in the Plückthun laboratory using 
unlabeled minimal medium and the functional expression levels were assayed by radioligand-
binding experiments (work of Jendrik Schoeppe). The main conclusion after an array of 
optimizations was that the final OD was generally lower than in rich medium (as expected), but 
the functional expression levels per cell were usually higher. The total functional expression per 
liter of culture was lower than in rich medium (approximately 1 mg/L for TM86V-ΔIC3B), but 
nevertheless, it was sufficient to tackle the next steps. 
A concern for most biophysical studies including NMR is the functional state of the 
purified protein. A significant fraction of expressed protein may be non-functional, due to 
denaturation during purification or because of improper folding during biosynthesis5. The latter 
may be particularly problematic for evolved variants, as the selection pressure was on maximal 
functional expression levels and not on minimal misfolded receptors. In other words, if a gain in 
functional expression is due to higher total expression levels of a particular variant, as 
documented for the parent mutant D0318, it is possible that the amount of misfolded receptors 
80 CHAPTER 4  
per cell is also increased. Considering this, it is worth mentioning that standard IMAC 
purifications sometimes resulted in relatively monodisperse peaks in subsequent SEC analyses 
(data not shown) for the most stable NTR1 variants in DDM (not for D03), which is certainly an 
indication for a very low aggregation tendency in this particular detergent. Due to the small 
protein size compared to the large micelles, SEC gives however very little information on the 
structural integrity of non-aggregated GPCRs, implying that non-native – but nevertheless 
soluble – receptors can well go undetected. In crystallization trials, this type of sample 
inhomogeneity is disadvantageous, but it does not necessarily prevent crystal genesis entirely, 
as lattice formation itself can act as a purification step selecting for natively folded receptors. For 
NMR, on the other hand, sample inhomogeneity inevitably reduces spectral quality, as the entire 
protein ensemble of a sample is under investigation. In my opinion, it is thus very likely that 
ligand column-based purifications, which isolate functional proteins only, are beneficial for 
biophysical experiments. 
In order to enable our collaborators at Harvard Medical School (Wagner group) to 
perform optimal NMR experiments, the ligand column technology (see Chapter 2) was 
transferred to their laboratories. The transfer included the pD-NT construct, receptor plasmids 
(TM86V-ΔIC3B, HTGH4-ΔIC3B), various protocols and hands-on practical teamwork in Boston 
together with Dr. Franz Hagn, who is working independently on this project by now. Note that all 
NMR experiments described herein were performed by Dr. Hagn with me as a purification 
specialist accompanying many measurements. 
4.2.2.  Detergent and temperature optimization using 1H- 15N TROSY experiments 
NMR spectral qualities are critically affected by the size of the receptor-micelle complex 
and by the stability of the receptor. There is a potential trade-off between the use of short-chain 
detergents (small micelles) that are rather destabilizing, and the application of amphiphiles with 
longer aliphatic tails (large micelles), which are milder. Moreover, alternative detergents can 
affect NMR data quality also in other ways: They may influence conformational GPCR dynamics 
and varying exchange rates at the detergent-protein interface can be exhibited, so that specific 
resonances may either be visible or not. It is non-obvious, which one of the parameters is the 
most critical for NMR spectral quality, implying that empirical testing of alternative detergents is 
required to optimize the spectra for assignment. 
In order to collect the first NMR spectra in the Wagner laboratories and to determine 
whether the project is feasible, the most stable NTR1 variant was used (HTGH4). HTGH4-ΔIC3 
was expressed in 15N-labeled M9 minimal medium using D2O as a solvent. The receptor was 
purified according to the principles described in Chapter 2, but with detergent exchange at the 
SP sepharose column stage. Milligram quantities of perdeuterated 15N-labeled HTGH4 were 
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prepared in either 0.05 % (w/v) DDM, 0.3 % (w/v) DM, 0.2 % (w/v) OGNG and 0.1 % (w/v) 
DH7PC. Small fractions of the purified receptors were used to record irreversible temperature 
unfolding curves using circular dichroism (CD) spectroscopy (Figure 4.2). As expected, the 
maltoside detergents allowed high thermostabilities, but they generated comparably large 
micelles. OGNG was previously observed to be rather mild in crystallization trials, while still 
generating small micelles. This could indeed be confirmed here, as HTGH4-ΔIC3 exhibited the 
smallest apparent molecular weight in the SEC analysis in OGNG and at the same time it was of 
similar thermostability as in DM. DH7PC is frequently used as a membrane mimic for NMR 
experiments. This amphiphile resulted in slightly smaller micelles compared to DM, but the 
receptor unfolded at 3°C higher temperature. 
 
Figure 4.2  Purification and thermostability analyses of HTGH4-ΔIC3 in alternative detergents. 
Quantitative S200 analyses (left) representing the final step of a purification procedure according to 
chapter 2. Dimerization shoulders are observed for the maltoside detergents and to a lesser extent for 
DH7PC. The relative shoulder heights are concentration dependent, but reducing agent independent (data 
not shown). Oligomerization is potentially disadvantageous for NMR, due to the expected decrease in 
molecular tumbling rates and further loss of sensitivity. No shoulders are observed in OGNG. The thermal 
unfolding curves are based on helical content measurements by CD spectroscopy (right). The 
cooperativity of the irreversible transitions strongly implies that helical content is a valid relative measure 
of structural integrity in the case of HTGH4-ΔIC3. DH7PC appears to be a reasonable compromise between 
particle size and thermostability. This figure was adapted from a report prepared by F. Hagn. 
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1H-15N TROSY spectra were recorded in the neurotensin-bound states in the four 
detergent conditions. Generally, the spectral qualities were highly promising, as a large fraction 
of the expected amide resonances could be observed. As expected from the unfolding transitions 
above 69°C, the spectral qualities improved for all detergent conditions with increasing 
temperatures up to 47°C (Figure 4.3). Surprisingly, however, the detergent exhibiting the 
smallest micelles (OGNG) produced the poorest spectrum, which might have been due to 
adverse receptor dynamics in this detergent or because of unfavorable exchange kinetics of this 
particular amphiphile with the receptor. Comparing the spectra in both maltosides, it appeared 
that the peak numbers were very similar, but the resonances were significantly better defined in 
DM. This implied, that the micelle size was the limiting parameter regarding spectral quality in 
the case of DDM and not receptor stability, which was in agreement with the thermostability 
analysis. The most useful behavior of HTGH4-ΔIC3 for NMR assignments appeared to occur in 
DH7PC, as the largest fraction of expected backbone amide resonances (approximately 250 out 
of 330) was visible in these TROSY spectra (e.g. compare the number of amide resonances from 
glycines above 8 ppm (δ2 1H) and below 113 ppm (δ1 15N)) and since the peaks were well 
defined. A qualitative comparison of the HTGH4-ΔIC3 spectrum in DH7PC at 47°C with a 
previously assigned spectrum of a protein of similar size (Gαi, data not shown), suggested that it 
might be feasible to assign the majority of HTGH4-ΔIC3 resonances to specific backbone amides 
in this condition using triple labeling strategies and higher dimensional NMR experiments. 
 
Figure 4.3  1H-15N TROSY spectra of HTGH4-ΔIC3 at different temperatures and in different detergents. 
The receptor-neurotensin complex concentrations were at 100 to 200 µM and the spectra were recorded 
over night. The same sample was used for all three spectra of one detergent condition. Experiments were 
performed in a sequence from low to high temperatures. Approximately 250 resonances are observable 
(maximally expected ≈330). This figure was adapted from a report prepared by F. Hagn. 
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4.2.1.  Evidence of changing receptor dynamics upon binding of different ligands 
One of the first experiments that was carried out after condition optimization was 
antagonist competition. As described above, the initial 1H-15N TROSY spectra were obtained after 
applying the best established ligand-purification method, which resulted in preparations of 
neurotensin-bound receptors (HTGH4-ΔIC3 in complex with the unlabeled cleavage product 
from the ligand column). Subsequently, 2 mM unlabeled NTR1-antagonist (SR142948) was 
added to the NMR sample (100 µM HTGH4-ΔIC3 in DH7PC) and another 1H-15N TROSY spectrum 
was recorded (Figure 4.4B). Interestingly, a large fraction of peaks either disappeared or 
changed their position. The fact that not all resonances were perturbed, implied that HTGH4-
ΔIC3 might still have retained a native fold after adding excess antagonist. Additionally, Dr. Hagn 
could show that antagonist binding leads to an almost 10°C increase of the thermal unfolding 
transition (Figure 4.4A), which is in agreement with native receptor-antagonist interactions as 
well. If the 1H-15N TROSY spectrum in the presence of excess antagonist indeed represents an 
antagonist-bound and natively folded receptor, the missing resonances are likely due to an 
increased fraction of backbone amides in intermediate exchange. Few missing peaks may be 
explained by direct effects at the ligand binding site, but the large extent of peak disappearance 
suggests that the agonist-antagonist replacement must have indirect effects on major parts of 
the receptor and its dynamics, including residues that are clearly remote from the ligand binding 
sites.  
Notably, in the Plückthun laboratory, an array of experiments suggested that neurotensin 
binds practically irreversibly or with very low off-rates to the evolved variants (examples in 
chapter 2). This is not necessarily contradicting the NMR ligand-competition experiment, as the 
assays in the Plückthun group were performed at 4 – 20°C in maltoside or glucoside detergents 
for crystallographic purposes. The NMR and CD spectroscopy experiments in the Wagner 
laboratories, were, however, carried out using receptors prepared in DH7PC and at much higher 
temperatures, which may allow increased neurotensin off-rates. In fact, a similar competition 
experiment in DDM did not reveal particular spectral differences (personal communication F. 
Hagn), suggesting that the choice of detergent indeed critically affects the off-rate of 
neurotensin. 
A technical challenge of NMR experiments in the context of membrane proteins should, 
however, be considered as well. Apparently, chemical shifts and their perturbations are 
dependent on the environment of the nuclei under investigation. When analyzing the effect of a 
ligand, it is crucial that the ligand and the protein can be provided in exactly the same solvent, 
otherwise global or potentially also local perturbations can occur, which are ligand-independent. 
This is challenging for MPs, when detergents are used as membrane mimics, since the protein 
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concentration step usually enriches empty micelles in an unpredictable way. Without 
determining the total detergent concentration in the MP sample by a separate assay, it is thus 
hardly possible to dissolve the ligand in exactly the same buffer and large differences in 
detergent concentrations may occur. In my opinion, it is therefore important to verify the results 
of the antagonist competition experiment using an alternative membrane mimic, which does not 
cause this particular problem. 
 
Figure 4.4  Effect of antagonist SR142948 on thermostability and on the 1H-15N TROSY spectrum of 
HTGH4-ΔIC3 in DH7PC. These experiments were carried out by Dr. F. Hagn based on samples that were 
purified according to the principles described in Chapter 2, which resulted in neurotensin-bound receptor 
preparations. A, the addition of excess antagonist leads to an increased thermal denaturation transition 
point. As only one transition is observed, it can be concluded that all receptors are bound to antagonist 
under these condtions. If only a fraction of the receptors would be in complex with the antagonist, two 
transitions would be expected. B, The spectrum of HTGH4-ΔIC3 at 100 µM in complex with unlabeled 
neurotensin before (top) and after adding 2 mM unlabeled antagonist (bottom). This figure was adapted 
from a report prepared by F. Hagn. 
 
4.3.  Outlook and research suggestions 
4.3.1.  Nanodisc reconstitution 
A nanodisc is a patch of phospholipids of defined size, which is encircled by two copies of a 
membrane scaffold protein (MSP)19. It is possible to reconstitute MPs into this bilayer particle, 
which allows handling of the proteins in the absence of detergents20. A membrane mimic of this 
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type could be advantageous for NMR titration experiments, as it is a stable particle that – unlike 
detergent micelles – is not constantly exchanging components with the surrounding solution at 
high rates. Hence, empty nanodiscs can be removed after reconstitution, if appropriate 
chromatographic steps can be identified. Subsequently the “occupied” nanodiscs can be treated 
like soluble proteins, which is advantageous for NMR titrations, as well as for many other 
applications, where detergents may interfere (e.g. ligand screening, functional assays, ribosome 
display, etc.).  
During my stay in the Wagner laboratory in Boston, we started to develop reconstitution 
protocols based on previously described procedures and based on the practical experience of 
the lab members21; 22. After optimizing ratios between lipids, MSP and receptors, we identified 
conditions that allowed efficient reconstitution of evolved receptors into nanodiscs in small-
scale. Furthermore, a highly effective cation-exchange chromatography step was developed, 
which allowed separation of empty nanodiscs from those containing the receptors (Figure 4.5 . 
As analyzed by SEC, the small-scale nanodisc reconstitution resulted in homogeneous particles 
(Figure 4.5 A). In order to apply the nanodisc technology to the various studies in the near 
future, it is now necessary to establish scaled-up procedures that allow efficient reconstitution 
of mg quantities of evolved receptors.  
Nanodisc reconstitution is a multiparameter reaction that depends on a variety of 
practical aspects. According to my experience, the procedure described in the methods (section 
4.4.4) is highly reproducible as long as the same lipid and MSP stock solutions can be used. If 
new solutions are prepared (which was necessary during the optimizations in the Wagner 
laboratory) unwanted variability can occur. In order to establish the large-scale reconstitution 
reaction in the Plückthun group, I therefore recommend to run initially some pretests at small-
scale using similar MSP to lipid ratios to the ones we established in the Wagner laboratory. 
When the optimal MSP to lipid ratios are identified with the new stock solutions, large-scale 
reactions based on the same stocks can be established. 
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Figure 4.5  Small-scale reconstitution of HTGH4-ΔIC3 into nanodiscs. A, S200 (HiLoad 16/600) analysis 
directly after reconstitution (detergent removal by dialysis). The main peak corresponds to empty 
nanodiscs and receptor-containing nanodiscs. The peak at an elution volume of approximately 80 ml is 
due to the desired excess of MSP in the reconstitution reaction. The void peak at 40 ml and potential 
oligomerization shoulders are minor. B, Subsequent, cation exchange step, which allows specific binding 
of nanodiscs that contain receptors and their elution in a small volume. Due to the low pI of MSP, empty 
nanodisc cannot bind to the column material at the chosen pH (verified by SDS-PAGE analysis). 
 
4.3.1.  NMR assignment 
The most promising 1H-15N TROSY spectra were obtained using the variant HTGH4-ΔIC3B. 
TM86V, the only mutant that was characterized in terms of Gi signaling and β-arrestin-mediated 
internalization, was tested as well (construct TM86V-ΔIC3B). The obtained spectra of the latter 
were very similar, but of slightly lower quality (data not shown). The two variants are only 
different at 12 amino acid positions, suggesting that the assignment should be carried out using 
HTGH4-ΔIC3. It may then be transferred to the signaling-active TM86V-ΔIC3B in a subsequent 
step. Alternatively, HTGH4-ΔIC3B, which was not characterized in signaling assays so far, can be 
characterized in terms of function. If experiments reveal that this variant exhibits residual 
signaling activity as well, a transfer of the assignment may not be necessary. 
4.3.2.  Generating additional insights into NTR1 function by crystal structures 
To improve our understanding of receptor function, it is crucial to obtain further high-
resolution structures of NTR1 mutants in alternative states. Mattia de Luigi and Philipp Heine 
from the Plückthun group are currently working on the crystallization of antagonist-bound 
TM86V-ΔIC3B and HTGH4-ΔIC3B. Using the mild LCP method, it may even be possible to obtain 
apo-state structures. Moreover, Jendrik Schoeppe, Abinav Kumar and Matthias Hillenbrand are 
establishing large-scale complex formation procedures of NTR1 variants with heterotrimeric G 
proteins. The SEC chromatograms of their complexes look promising as well, but further work is 
required to obtain crystals. 
4.3.3.  Suggestion: Engineering of mutants with specific signaling characteristics 
The extensive protein engineering efforts for crystallographic studies on GPCRs in the past 
years included the introduction of fusion proteins, mutations and artificial disulfide bridges. 
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Interestingly, for those GPCRs, where several approaches were successful, major global effects of 
these modifications on the structures were rarely observed. But at the same time, signaling 
activity was usually affected very strongly. TM86V-ΔIC3 is one of the rare cases that exhibits 
residual signaling towards G proteins, and considering its benefits in terms of expression and 
stability, it could be a starting point to reengineer specific signaling characteristics of the wild-
type receptor. The motivation behind this suggestion is explained in the following paragraphs. 
Over the course of natural evolution, wild-type NTR1 experienced likely only a very weak 
selection pressure for high stability. It evolved to couple to various different G proteins and to 
interact with GRKs, β-arrestins and potentially with other regulatory proteins. Binding to 
various signaling partners likely requires structural plasticity, which could be one of the reasons 
for the observed instability of NTR1 (even in the mildest detergents). Low stability may even be 
a functional requirement that allows rapid receptor turnover upon activation, which is typical 
for GPCRs. However, the application of directed evolution lead to mutations that improved the 
stability at the cost of reduced signaling activity.  
In the short term, the NMR studies and the complex crystallization trials could be 
supported by assays that reveal the effects of all individual TM86V mutations on signaling. As 
previously reported, most mutations appear to have minor, but additive effects on the 
expression levels and the stability18. Rather weak or even neutral mutations in this regard could 
nevertheless dramatically affect the signaling behavior. For example, the selected mutation 
R1673.50L appears to improve stability only slightly or not at all, but it strongly affects basal and 
agonist-bound signaling of TM86V-ΔIC3A. Identifying further positions of this type would allow 
to use more appropriate NTR1 variants in NMR, which simulate the natural activation 
mechanisms more accurately. Furthermore, a so called “minimal mutant” with similar 
expression and stability as TM86V but higher signaling levels would also be beneficial for 
complex crystallization trials, as it may interact more efficiently with G proteins. The generation 
of such a receptor variant may require the introduction of alternative mutations that further 
stabilize specific receptor regions, which are not involved in the conformational changes 
necessary for signaling (e.g. at the TM1-TM2 or at the TM7-TM1 interfaces). These additional 
mutations may be rationally designed based on the crystal structures and/or using in silico free-
energy calculations. 
It is important to note that stability and signaling are not mutually exclusive. Natural 
selection itself has generated GPCRs with very high stabilities that seem to act as efficient binary 
switches, such as rhodopsins, which couple specifically to Gt. Furthermore, artificial engineering 
of certain wild-type GPCRs has also been carried out in the past, so that the receptors interacted 
preferentially with designed ligands23; 24. Similar to my suggestion, some “designer GPCRs” even 
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activated only G proteins of a specific Gα subtype. In these cases, however, the wild-type 
receptors already signaled via one specific Gα and only the ligand specificity was changed 
(usually by abolishing binding to the natural ligand via a point mutation, while maintaining 
interactions with a specific pharmacological compound). Since the engineered receptors with 
alternative G protein specificity were based on different wild-type receptors, the amino acid 
sequences are, however, so different that the G protein specificity determinants remained 
obscure.  
In the long-term, an idea would be to engineer a GPCR, which already couples to various 
signaling partners as a wild-type, so that each derived variant activates only one specific natural 
downstream interaction partner. If this was achieved using stable NTR1 variants, the different 
pharmacological behaviors could be rationalized based on data from the various technologies 
that are uniquely suitable for this particular model GPCR. NMR, crystallography and DEER 
spectroscopy (DEER benefits from perdeutaration23 as well), applied to such receptors, have the 
potential to answer key questions regarding GPCR activation mechanisms, biased-signaling and 
G protein specificity. Furthermore, the receptors may be applied in cellular model systems, 
where they could mimic the effects of perfectly biased GPCR ligands. An improved 
understanding of GPCR signaling mechanisms and of cellular responses of biased receptors 
would facilitate the design of ligands that stimulate specific downstream cascades, thus limiting 
“on-target side effects”. 
Notably, Matthias Hillenbrand has established a reproducible signaling assay procedure in 
a 96-well format, where individual G proteins and GPCRs with known absolute protein 
concentrations can be freely combined. His work also provided data on the stability (or 
instability) of several dozen heterotrimeric G protein subunit combinations. The availability of 
all these cloned constructs as viral particles for Sf9 insect cell infection is an excellent basis for 
the engineering of specific signaling characteristics. While signaling screening procedures are 
established in this laboratory, evolution methods with directed selection pressures towards 
signaling are currently not available. Methods of this type may support the above-mentioned 
project idea and they would likely reveal further details about GPCR activation principles. 
 
4.4.  Materials and Methods 
4.4.1.  Expression in minimal medium (adapted Wagner-lab protocol) 
Expression for 1H–15N TROSY experiments was carried out in the E. coli strain BL21 Tuner 
using the same pBR322-derived vector as for crystallographic purposes (chapter 2, 3 and 5 24). 
The cells were freshly transformed for each expression and directly cultivated in 5 ml LB 
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containing 1 % (w/v) glucose and 100 µg/ml ampicillin at 37°C overnight. The saturated culture 
centrifuged at 4’000 g for 5 min and the cells were resuspended in 500 µl LB. 100 ul of the 
resuspension was then mixed to 5 ml LB-D2O containing 1 % (w/v) glucose and 100 µg/ml 
ampicillin. The culture was incubated for 7 h at 37°C and subsequently centrifuged at 4’000 g for 
5 min. All cells were transferred to 50 ml of M9-D2O minimal medium containing 1 % (w/v) 
glucose, 100 µg/ml ampicillin and 1 g/l 15NH4Cl. The pre-culture was incubated overnight at 
37°C. One liter of pre-warmed M9-D2O minimal medium containing 1 % (w/v) glucose, 100 
µg/ml ampicillin and 1 g/l 15NH4Cl was subsequently inoculated to an OD of 0.05. The culture 
was incubated at 37 °C and induced at an approximate OD of 0.7 by 1 mM IPTG. One hour before 
induction, the temperature of the culture was lowered to 30°C. The induction period was 16 – 20 
h. Cell pellets were stored at -80°C. 
4.4.2.  NMR experiments on TM86V-ΔIC3 and HTGH4-ΔIC3 
Purification of TM86V-ΔIC3B and HTGH4-ΔIC3B for NMR experiments was carried out 
according to the protocol described in Chapter 2 by means of the non-mutated neurotensin 
ligand column (pD-NT). The only exception to the aforementioned procedure was that detergent 
exchange to either 0.05 % (w/v) DDM, 0.2 % (w/v) OGNG or 0.1 % (w/v) DH7PC was performed 
during cation exchange chromatography and not at the ligand column step. After the final SEC 
step (Superdex 200 10/300 GL column) the receptors were concentrated to 100 – 200 µM for 
1H–15N TROSY experiments, which were conducted at Bruker AvanceIII 600 or 800 MHz 
magnets at 303, 313 or 323°K, respectively.  
4.4.3.  Circular dichroism (CD) spectroscopy 
Purification of HTGH4-ΔIC3 for NMR experiments was carried out according to the 
protocol described in Chapter 2 by means of the non-mutated neurotensin ligand column (pD-
NT). CD spectroscopy was performed at a Jasco CD Spectropolarimeter J-810 at a protein 
concentration of 5 µM. Thermal transitions were recorded using purified receptors at a 
concentration of 5 µM in the buffer of the final SEC run. Cuvettes of 0.1 cm pathlength were used. 
The secondary structure changes were monitored at a wavelength of 220 nm using a heating 
rate of 60 K/h. Fitting of the thermal unfolding profiles was carried out assuming a two-state 
folding mechanism25. 
4.4.4.  Nanodisc reconstitution 
The best reconstitution results were obtained in the following way at 4°C: After the last 
purification step (Superdex 200 10/300 GL column), TM86V-ΔICB was frozen in liquid nitrogen 
for storage at a concentration of 0.53 mg/ml in 10 mM HEPES pH 8, 2 mM DTT, 150 mM NaCl, 
0.02 % (w/v) DDM, 30 % (v/v) glycerol and 100 nM NTI (chemically synthesized ligand, 
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corresponding to the proteolytic cleavage product after ligand column elution). After thawing on 
ice, the protein was concentrated to less than a tenth of its volume (50 kDa cutoff Amicon Ultra-
15), followed by dilution to the original volume using a buffer containing 20 mM TrisHCl pH 7.4, 
100 mM NaCl, 0.5 mM EDTA, 0.02 % (w/v) DDM, 250 nM NTI and 2 mM DTT (buffer exchange). 
Subsequently, the receptor concentration was increased to 100 µM using the same concentrator. 
A stock concentration of 50 mM of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
was prepared in a buffer containing 100 mM cholate, 20 mM TrisHCl pH 7.4, 100 mM NaCl and 
0.5 mM EDTA. The stock of MSP1D121 was prepared at 600 µM in 20 mM TrisHCl pH 7.4, 100 
mM NaCl and 0.5 mM EDTA (note that the membrane scaffold protein tends to be insoluble at 
concentrations above 1 mM). 
Using these stock concentrations a 150 µl reconstitution reaction mixture was prepared in 
an Eppendorf tube by adding 55 µl MSP1D1, 21 µl POPC, 44 µl buffer (20 mM TrisHCl pH 7.5, 
100 mM NaCl, 0.5 mM EDTA, 2 mM DTT) and 30 µl TM86V-ΔICB. Note that the receptor was 
added last after gently mixing the previous components. The final concentrations were 220 µM 
MSP1D1, 7 mM POPC, 20 µM TM86V-ΔIC3B, 14 mM cholate (CMC: 6 – 14 mM), 0.4 – 4 mM DDM, 
20 mM TrisHCl pH 7.4, 100 mM NaCl, 0.5 mM EDTA, 2 mM DTT, 50 nM NTI and trace 
concentrations of buffer components from the receptor preparation that were not entirely 
exchanged. The mixture was incubated for 1 – 2 h on ice, followed by dialysis against 3 × 300 ml 
of a buffer containing 20 mM TrisHCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 2 mM DTT and 10 nM 
NTI (Slide-A-Lyzer Mini Dialysis Unit; 10 kDa cutoff) over a total of 3 days.  
The nanodisc reconstitution mixture was diluted 5-fold by SP buffer A containing 20 mM 
HEPES pH 6.5 and 2 mM DTT. Subsequently it was subjected to a pre-equilibrated SP Sepharose 
column (0.25 ml bed volume, bench top) using gravity flow. The column was washed by 2 ml SP 
buffer A and subsequently, the nanodiscs containing receptors were eluted by 4 × 100 µl SP 
buffer B containing 20 mM HEPES pH 6.5, 2 mM DTT, 250 nM NT1 and 450 mM NaCl. 
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5.1.1.  Abstract 
The largest single class of drug targets is the G Protein-Coupled Receptor (GPCR) family. 
Modern high-throughput methods for drug discovery require working with pure protein, but 
this has been a challenge for GPCRs, and thus the success of screening campaigns targeting 
soluble, catalytic protein domains has not yet been realized for GPCRs. Therefore most GPCR 
drug screening has been cell-based, whereas the strategy of choice for drug discovery against 
soluble proteins is HTS using purified proteins coupled to structure-based drug design. While 
recent developments are increasing the chances of obtaining GPCR crystal structures, the 
feasibility of screening directly against purified GPCRs in the unbound state (apo-state) remains 
low. GPCRs exhibit low stability in detergent micelles, especially in the apo-state, over the time 
periods required for performing large screens. Recent methods for generating detergent-stable 
GPCRs, however, offer the potential for researchers to manipulate GPCRs almost like soluble 
enzymes, opening up new avenues for drug discovery. Here we apply Cellular High-throughput 
Encapsulation, Solubilization and Screening (CHESS) to the neurotensin receptor 1 (NTS1) to 
generate a variant that is stable in the apo-state when solubilized in detergents. This high 
stability facilitated the crystal structure determination of this receptor and also allowed us to 
probe the pharmacology of detergent-solubilized,apo-state NTS1 using  robotic ligand binding 
assays. NTS1 is a target for the development of novel antipsychotics and thus CHESS-stabilized 
receptors represent exciting tools for drug discovery. 
 
Keywords:  G Protein-Coupled Receptor, directed evolution, CHESS, stabilization, 
encapsulation, detergent, apo-state, thermostability. 
Abbreviations:  GPCR, G protein-coupled receptor; IMP, integral membrane protein; 
CHESS, cellular high-throughput encapsulation solubilization and 
screening; NT, neurotensin peptide; FACS, fluorescence-activated cell 
sorting; EDTA, ethylenediamine tetraacetic acid; DDM, n-dodecyl-β-D-
maltopyranoside; DM, n-decyl-β-D-maltopyranoside; OG, n-octyl-β-D-
glucopyranoside; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate; CHS, cholesteryl hemisuccinate; HTG, n-heptyl-β-D-
thioglucopyranoside; HTS, high-throughput screening; PBS, phosphate 
buffered saline; sfGFP, super-folder green fluorescent protein. 
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Highlights: • NTS1 was stabilized in harsh, short-chain detergents using CHESS,  
  generating NTS1-H4 
• NTS1-H4 exhibited a 26.8°C improvement in apo-state thermostability 
• Apo-state NTS1-H4 could be stored for hours without significant loss of 
activity 
• Solubilised apo-state NTS1-H4 was used for in vitro, high-throughput 
binding assays 
• The crystal structure of NTS1-H4 in short-chain detergent was recently 
solved 
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5.1.2.  Introduction 
GPCRs are located in the cell membranes of all human cell types where they serve to detect 
and transduce extracellular signals into intracellular signaling pathways. The GPCR gene family 
is the largest in the human genome and encodes approximately 850 different receptors that 
sense and respond to a huge variety of stimuli including neurotransmitters, metabolites, 
hormones and environmental stimuli such as light, tastes and smells [1]. This diverse array of 
stimuli is a testament to the evolutionary success of the protein architecture of GPCRs, made up 
of seven transmembrane spanning domains, which is maintained throughout the family despite 
low sequence homology. Upon activation, GPCRs couple with, and stimulate intracellular G-
proteins to initiate cellular signaling pathways.  
Because of the location of GPCRs on the surface of cells and their involvement in many, if 
not most, physiological pathways, GPCRs are the major class of drug targets in the human body 
[2]. Conversely, less than 10% of the GPCR family is currently targeted by prescription drugs [2]. 
This discrepancy is primarily due to the lack of knowledge about how molecules interact with 
and activate GPCRs at the molecular level, such that a true molecular design of specific agonists 
and antagonists has not been possible. Additionally, for a great number of receptors, neither the 
natural ligand nor the function have been elucidated ("orphan receptors"). Most drugs have thus 
come from cellular screening of the known receptors. 
Modern drug discovery techniques for targeting soluble enzymes for example, have higher 
success rates based on improved in vitro screening assays and the parallel application of surface 
plasmon resonance (SPR) or nuclear magnetic resonance spectroscopy (NMR) based fragment 
screening in conjunction with structure based lead optimization [3]. The hurdle for structural, 
mechanistic and in vitro drug screening studies of GPCRs is that to apply a similar workflow to 
GPCRs, the receptors must be solubilized in detergents and purified. However, GPCRs typically 
exhibit low stability in detergent micelles, especially when a sample is required to be stable in 
the apo-state for many hours to facilitate in vitro binding assays and fragment screening using 
biophysical methods. 
Recent progress in obtaining crystal structures of GPCRs [4-19] will undoubtedly aid in the 
computational optimization of drug leads. Most of these structures were solved as fusion 
proteins, with T4-lysozyme replacing intracellular loop 3 [5, 20], which acts as a rigid scaffold 
that promotes the formation of crystal contacts in lipidic-cubic phase crystallization trials. The 
fusion strategy is necessary so that sufficient protein surface area is displayed outside of the 
lipid bilayer, because for most unmodified GPCRs, virtually all of the protein is embedded within 
the bilayer and thus unable to contribute to crystal contact formation. This technique does not 
significantly increase the stability of the receptor in the solubilised state [20, 21] and, because 
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the receptors are reconstituted into insoluble media, this strategy is not useful for direct high-
throughput screening for interacting molecules. Furthermore, such a fusion disallows 
interaction between the GPCR and G proteins so that signaling as a readout is not an option. 
A pioneering approach to making GPCRs more accessible to structural, biochemical and 
biophysical methods is to stabilise the receptors by introducing thermostabilizing mutations. 
Stabilising mutations have been identified using semi-rational or alanine-scanning and screening 
approaches [5, 22-26], and with directed evolution methods [27-31]. Stabilized GPCRs can be 
successfully applied to crystallization [7, 14, 19, 32-35], robotic in vitro binding assays in the 
solubilised form [31] and fragment screening using biophysical methods [36, 37]. Generally, 
these studies require the receptor to be purified in the presence of a ligand to stabilise the 
receptors during the time needed for purification and assay setup. This necessitates extensive 
washing to remove bound ligand before assays can be conducted [36], and the instability of 
these receptors in the apo-state may limit the time that samples can be probed to unrealistic 
intervals. To enable reliable measurements of GPCR samples over the time scales required for 
high-throughput screening (HTS) assays or NMR-based fragment screening, receptors are 
required that are stable for many hours, preferably in the apo-state. Here we use the Cellular 
High-throughput Encapsulation, Solubilization and Screening (CHESS) method to evolve 
neurotensin receptor 1 (NTS1) mutants that meet these requirements. The crystal structure of 
one of the resultant receptors was recently solved in a detergent-solubilized form [19]. Here we 
demonstrate that the long-term, apo-state stability of these CHESS-stabilized NTS1 variants 
makes them suited to HTS-compatible ligand binding assays using isolated receptors in 
detergent micelles. 
5.1.3.  Materials and Methods 
5.1.3.1 Stabilisation of NTS1 using CHESS 
E. coli strain DH5α was transformed with the StEPM303 library and receptor expression 
was induced as described previously [29, 31]. 1.75 x 1010 cells from the expression culture were 
encapsulated with one layer of chitosan and 1 layer of alginate as described previously [31]. For 
the initial selection round, the capsule population was exposed to PBS pH 7.4, 1 mM EDTA and 
1.7% DM (termed PBS-E(DM)) for 3 h at 20°C with vigorous shaking without ligand, followed by 
2 h at 20°C in the presence of 20 nM BODIPY FL-labeled NT(8-13) (FL-NT). Capsules were 
washed twice in PBS-E(DM) and subjected to FACS using a FACSAria III cell sorter (BD 
Biosciences), where capsules were sorted that exhibited fluorescence placing them in the top 0.5 
– 1% of the population, resulting in the collection of 50,000 capsules. Genetic information was 
recovered from sorted capsules by PCR amplification using NTS1 specific primers after 
incubation in an ultrasonic water bath for 5 minutes. For the second round of selection, the 
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amplified receptor genes were re-cloned, proteins expressed and the cells encapsulated as 
above. The capsule population was first treated with PBS-E(DM) for 3 h at 20°C, followed by 
addition of 20 nM FL-NT for 1 h at 20°C, before the capsules were collected by centrifugation 
and resuspended in PBS-E containing 2% octyl-β-D-glucopyranoside (OG) (PBS-E(OG)) and 20 
nM FL-NT at 4°C. Capsules were washed once in 20 nM FL-NT in PBS-E(OG) to promote efficient 
detergent exchange before being incubated for 2 h in PBS-E(OG) with ligand at 4°C. Capsules 
were washed twice in PBS-E(OG) and subjected to FACS as above, resulting in the collection of 
38,000 capsules. These clones were isolated and re-cloned as above for a third round of 
selection. In the third round of selection, the capsules were exposed to PBS-E(DM) for 3 h at 
20°C, followed by addition of 20 nM FL-NT for 1 h at 20°C, before the capsules were collected by 
centrifugation and resuspended in PBS-E containing 2% heptyl-β-D-thioglucopyranoside (HTG) 
(PBS-E(HTG)) and 20 nM FL-NT at 4°C. Capsules were washed once in 20 nM FL-NT in PBS-
E(HTG) to promote efficient detergent exchange before being incubated for 25 h at 4°C. After 
this step, capsules were washed twice in PBS-E(HTG) and sorted with FACS as above, resulting 
in the collection of 20,000 capsules. The DNA encoding these clones was isolated and re-cloned 
into an expression vector containing a C-terminal sfGFP fusion, as in [31]. The CHESS workflow 
is depicted in Figure 5.1. 
5.1.3.2 Stability analysis of 96 individual NTS1 variants from the selected population 
Forty-seven individual colonies derived from the capsules sorted in the 3rd round of 
CHESS were picked and used to inoculate 1.2 ml cultures of LB broth containing 100 µg/ml 
ampicillin and 1% glucose in a 96-deep-well plate. As a control, a colony of cells transformed 
with a previously stabilised NTS1 variant (C7E02) [29] was also picked. Cultures were grown for 
16 h at 37°C before being used to inoculate 48, 5-ml-expression cultures in 24-deep-well plates. 
Receptors were expressed as described previously at 20°C for 20 h [31]. The initial cultures 
were centrifuged and the plasmid DNA isolated. After expression, cell pellets were solubilised in 
1 ml PBS-E(DM) for 2 h at 20°C and the cell debris pelleted with centrifugation at 5000 g for 20 
min. 0.8 ml of the supernatant was transferred to a 96-well KingFisher plate (Thermo Scientific) 
containing 20 µg of streptavidin T1 Dynabeads (Life Technologies) per well. Samples were then 
robotically manipulated using a KingFisher Flex robot (Thermo Scientific) as described 
previously [31], including binding of 20 nM HL-NT for 1 h, exchanging the detergent to 2% HTG 
for 1.5 h, washing away unbound ligand for 5 min and eluting the beads into 0.25 ml PBS-E(HTG) 
for analysis of ligand binding in a fluorescent plate reader (Tecan M1000) and with flow 
cytometry (Partec CyFlow Space). 100,000 beads from the binding assay were measured with 
flow cytometry, with the average fluorescence intensity of single-sized beads presented in 
Figure 5.2B upon 638 nm laser excitation and emission at 675 nm (20 nm bandpass).   
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5.1.3.3 Construct optimization 
Based on the stability screen, the most promising stabilized variant, number 47 (termed 
NTS1-H4) was sequenced. Before further analysis with fluorescent binding assays, the following 
changes were made to the receptor. A mutation in the conserved E/DRY motif was reverted 
(L167R), a potential human rhinovirus 3C protease site was removed from intracellular loop 3 
(Q274A), alanine 342 in extracellular loop 3 was reverted to the naturally occurring 
phenylalanine (A342F) and all exposed cysteines were mutated to either alanine or serine 
(C278A, C386A, C388A, C417S). The resultant receptor was termed NTS1-H4(BM1) and the 
encoding gene was synthesized by Genscript.  
5.1.3.4 Stability comparison of engineered NTS1 variants 
Stability measurements of selected NTS1 receptor variants were performed as described 
previously [28, 31]. NTS1 receptor variants were expressed with a C-terminal sfGFP-Avi-tag 
fusion. A cell pellet corresponding to a 2.5 ml expression culture was used for one single 
measurement reporting functionally folded receptor as determined by a ligand binding assay. 
Receptors were solubilized in solubilization buffer (PBS pH 7.4, 1% (w/v) DDM, 0.5% (w/v) 
CHAPS, 0.1% (w/v) CHS, 1 mM EDTA, Complete protease inhibitors (Roche), 40 µg/ml 
deoxyribonuclease I (Roche), 1 mg/ml lysozyme). Solubilization was performed at 4°C for 2 h. 
Cell debris was removed by centrifugation and the supernatant was exposed to streptavidin-
coated paramagnetic beads. Solubilized receptor variants were allowed to bind to the beads for 
1 h at 4°C before being transferred in 96-well plates for subsequent manipulation with a 
KingFisher Flex magnetic particle processor. Receptor-coated beads were subjected to detergent 
solution, PBS-E(DCC) (PBS pH 7.4, 1 mM EDTA, 1% (w/v) DDM, 0.5% (w/v) CHAPS, 0.1% (w/v) 
CHS) with or without 20 nM Hilyte-647 labeled neurotensin 8-13 (HL647-NT). Non-specific 
binding was determined by adding excess (1 µM) unlabeled NT8-13 competitor to the binding 
solutions. After a further 0 h or 18 h exposure to DDM, beads were washed twice with PBS-
E(DCC) and those exposed to detergent in the unbound state were transferred to solutions 
containing 20 nM HL647-NT with or without competitor for 1.5 h. Receptor-coated beads were 
washed twice in PBS-E(DCC) and transferred to black 96-well microplates (Greiner) in a final 
volume of 100 µl. HL647-NT and sfGFP fluorescence levels were measured in each well using an 
M1000 dual monochromator fluorescence plate reader (Tecan) with excitation at 630 nm for 
HL647-NT and 488 nm for sfGFP. Fluorescence emission for HL647-NT was measured at 680 nm 
and for sfGFP at 530 nm. 
Thermal stability measurements in PBS-E(DCC) of NTS1 receptor variants were essentially 
performed as described for the analysis of detergent stability (see above). After exposure of 
solubilized receptor variants to streptavidin-coated paramagnetic beads, receptor-coated beads 
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were resuspended in PBS-E(DCC) with or without ligand (or competitor). Beads were 
transferred to 96-well PCR plates and exposed to different temperatures for 30 min in a gradient 
PCR cycler (Biometra). After heat treatment, receptor-coated beads that were heated in the 
absence of ligand were incubated with PBS-E(DCC) containing 20 nM HL647-NT or competitor 
for 1.5 h. Beads were washed twice in PBS-E(DCC) and transferred to black 96-well microplates 
and fluorescence intensities of HL647-NT and sfGFP in each well were determined as above. The 
data were analyzed by nonlinear regression fitting with GraphPad Prism. 
5.1.3.5 KingFisher saturation binding assays 
NTS1-H4(BM1) was expressed in 400 ml cultures for 20–24 h at 20 °C, the cells  harvested 
with centrifugation and the pellet resuspended in 10 ml 50mM HEPES (pH 7.8) containing 200 
mM NaCl, 10 mM EDTA, 1 mg/ml chicken lysozyme, 10 U/ml DNAse, 1.7% DM and 0.5% CHAPS. 
Cells were solubilized at 20°C with vigorous shaking for 3 h. Cell debris was removed with 
centrifugation at 15,000 g for 10 minutes at 4°C. The supernatant containing solubilized 
receptor was then incubated with streptavidin-coated paramagnetic beads, 2.5 µg of beads per 
ml of culture, at 4°C for 1 h to immobilize the biotinylated receptor onto the beads. Beads were 
collected with centrifugation at 5,000 g for 5 min and resuspended in assay buffer (50 mM 
HEPES (pH 7.8), 200 mM NaCl, 10 mM EDTA and 0.1% DM) at a final concentration of 100 µg 
beads per ml. 20 µg of beads were then added to 48 wells of a deep well KingFisher plate (plate 
1) (Thermo Scientific). A concentration series of Alexa-647 labelled neurotensin 8-13 (A647-NT) 
was made in assay buffer and 1 ml of each added to several wells of a separate KingFisher plate 
(plate 2). For each A647-NT concentration, a separate solution was made containing an excess of 
unlabeled neurotensin 8-13 (10 µM), with 1 ml of each being aliquoted into designated wells of 
plate #2. 200 µl and 100 µl of assay buffer was added to 48 wells of another two KingFisher 
plates, plate #3 and plate #4 respectively. A KingFisher 96 magnetic particle processor was used 
to automatically perform the following steps at 4°C: the beads were captured from plate #1 and 
transferred to plate #2, beads and ligand solutions were mixed for 2 h at 4°C, beads were 
transferred to plate #3 and washed for 1.5 min before being transferred to plate #4. Beads were 
transferred with a multichannel pipette from KingFisher plate 4 to a Greiner non-binding black 
96-well plate. The sfGFP (excitation filter 485 nm, band pass 12 nm, emission filter 520 nm, band 
pass 10 nm) and Alexa-647 (excitation filter 640 nm, band pass 10 nm, emission filter 670 nm, 
band pass 10 nm) signals from each well were measured using an Omega Polarstar plate reader 
(BMG Labtech). To determine if ligand depletion was occurring during the binding incubation, 
50 µl of the A647-NT solutions in KingFisher plate #2 were transferred to a Greiner non-binding 
fluorescence 96-well plate and the Alexa-647 signals of the wells compared. Data were analysed 
with Graphpad Prism, with curves fitted using the one site – total and nonspecific binding 
equations.  
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5.1.3.6 KingFisher competition binding assays 
Receptor-coated bead samples were prepared and aliquoted into KingFisher plate #1 as 
described in 2.5. In plate #2, concentration series of the various competitors were added, all in 
assay buffer supplemented with 2 nM A647-NT, 0.5 ml per well. Competitors included SR 48692 
(Tocris Biosciences and Sigma Aldich), SR 142948 (Tocris Biosciences), neurotensin 8-13 (Sigma 
Aldrich) and neurotensin 1-12 (synthesized by GL Biochem, Shanghai, China). The binding 
assays were performed using a KingFisher 96 robot and Omega Polarstar plate reader as in 2.5. 
Data were analysed using Graphpad Prism with curves fitted using the one site – fit Ki equation. 
Data from 3 separate experiments were pooled and the estimated Kd values for A647-NT 
calculated in 2.5 were used to fit the competition curves. 
 
5.1.4.  Results 
5.1.4.1 CHESS based evolution of apo-state stable NTS1 variants 
To evolve an NTS1 variant that could be purified in short-chain detergents for X-ray 
crystallization and exhibit apo-state and long-term stability in the solubilized form, we used the 
highly diverse StEPM303 library of NTS1 mutants and selected using CHESS following the 
strategy outlined in Figure 5.1. In each selection round, the encapsulated GPCRs were solubilized 
for three hours, at 20°C, in the absence of ligand to place selective pressure on apo-state 
stability. In the second and third rounds of selection, the encapsulated receptor population was 
exposed to the short-chain detergents OG and HTG respectively, placing selective pressure on 
the population for stability in detergents that are suitable for vapor diffusion crystallization of 
GPCRs. Finally, long-term stability was selected for by leaving the third generation of the 
evolving population of GPCRs in HTG for 25 h before selecting out the most stable clones with 
FACS.  
5.1.4.2 Isolating NTS1-H4 from the CHESS selected population 
The genes encoding the CHESS-selected NTS1 variants were isolated from the sorted 
capsules and cloned into an expression vector comprising C-terminal sfGFP and avi-tag (for in 
vivo biotinylation) fusions. The stability of 47 receptor variants was assayed by testing their 
ability to bind a fluorescently labeled neurotensin ligand after solubilization in HTG for 2 h and 
98 h (Fig. 5.2). In this assay, solubilized receptors were captured on streptavidin-coated beads 
and exposed to fluorescently labelled neurotensin 8-13 (HL-NT). The ability of each clone to 
bind ligand at the given time points was determined by washing the beads and measuring the 
amount of HL-NT bound to the beads with a fluorescent plate reader (Fig. 5.2A) and a flow 
cytometer (Fig. 5.2B). Of these receptors, clone 47 (NTS1-H4) was selected for further analysis 
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because of its ability to bind high levels of NT after 2 h and 98 h solubilized in HTG, when 
measured with both methods. 
5.1.4.3 Comparison of the stability of NTS1-H4 to other NTS1 variants 
To determine whether NTS1-H4 exhibited favorable long-term and apo-state stability, we 
compared the stability of this receptor to wild-type rat NTS1, a thermostabilized variant 
produced through systematic mutation by Shibata et al. [26] (NTS1-7m), and a highly optimized 
variant generated through bacterial display and systematic mutation by Schlinkmann et al. 
(TM86V) [29, 31]. Each receptor was expressed in E. coli with an sfGFP-avi-tag C-terminal 
fusion, resulting in the production of fluorescent, biotinylated receptor. Unmodified NTS1 is not 
stable in detergents such as DM, OG and HTG, so to enable comparison across the receptor 
variants, we solubilized the cells in a mild detergent mix (PBS-E(DCC)). Solubilized receptors 
were immobilized on streptavidin-coated beads and subjected to a range of temperatures for 30 
minutes in the presence (Fig. 5.3A) or absence (Fig. 5.3B) of fluorescently labelled neurotensin 
to generate thermostability curves. Such curves are commonly used to rank the stabilities of 
engineered GPCRs, and the temperature at which only half the receptor proteins are able to bind 
ligand is referred to as the apparent melting temperature (Tm). NTS1-H4 exhibited the highest 
thermostability of all the variants when heated in both the presence (Tm = 57°C) and absence 
(Tm = 48.1°C) of excess neurotensin (Fig. 5.3A-B). Thus, the thermostability of NTS1-H4 in this 
harsh detergent is improved by 21.6°C in the bound state and 26.8°C in the apo-state compared 
to unmodified NTS1.  
The relative amount of folded receptor in each of the samples was monitored after 3 h in 
the apo-state and either 21 h in the apo-state or with HL-NT bound at 4 °C. The relative levels of 
folded receptor were calculated by measuring the ratio of bound HL-NT fluorescence (level of 
folded protein) to the sfGFP fluorescence (total protein) in each sample at various time points. 
As expected, unmodified NTS1 displayed the lowest level of folded receptor under each 
condition, closely followed by NTS1-7m (Fig. 5.3C). Interestingly, for all the receptor samples, 
there was no significant difference in the relative NT binding levels after a 21 h incubation at 4°C 
in the presence of HL-NT. There was a striking difference however, when the solubilized 
receptors were incubated for 21 h at 4 °C in the absence of NT (Fig. 5.3C). Under these 
conditions, no binding of NT could be detected on NTS1, while NT binding to NTS1-7m and 
TM86V was decreased by 72% and 63% respectively, whereas only a 22% decrease in ligand 
binding was seen for NTS1-H4.  
5.1.4.4 Saturation binding of NT to solubilised NTS1-H4 
The high stability exhibited by NTS1-H4 in the apo-state indicated that this variant could 
be used to probe the binding of ligands to solubilized, isolated receptor preparations in a low-
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cost high-throughput compatible way. To demonstrate this, we expressed and captured NTS1-
H4-sfGFP onto magnetic beads and using a KingFisher magnetic particle processor and 
fluorescent plate reader, conducted saturation binding assays using Alexa647-NT (Fig. 5.4A). 
The ligand binding step was conducted for 2 h at 4°C in 1 ml of solution, which resulted in no 
significant ligand depletion, even at only 100 pM A647-NT (Fig. 5.4B). Non-specific binding was 
determined by measuring the binding of increasing concentrations of A647-NT in the presence 
of 1 µM unlabeled NT8-13. To control for differences in bead loading, sfGFP fluorescence was 
measured in each well and the specific binding was calculated as a ratio of A647-NT fluorescence 
to sfGFP fluorescence. Fitting the resultant data enabled us to estimate the Kd of A647-NT 
binding to NTS1-H4 at 0.65 nM ± 0.13.  
5.1.4.5 Competition binding assays using solubilised NTS1-H4 
To probe the binding of unlabeled ligands to solubilized NTS1-H4, competition binding 
assays were performed in the same robotic manner, using 2 nM A647-NT as the labelled ligand 
(Fig. 5.4C). Unlabeled agonists neurotensin 8-13 (NT8-13) and neurotensin 1-12 (NT1-12), along 
with antagonists, SR48692 and SR142948, were able to compete with A647-NT in a dose-
dependent manner (Fig. 5.4C). Using the estimated Kd value for A647-NT from the competition 
binding experiments we were able to fit Ki values for NT8-13, NT1-12, SR48692 and SR142948 
respectively (Table 5.1). 
5.1.4.6 Sequence of NTS1-H4   
NTS1-H4 was sequenced and found to contain 25 amino acid substitutions over wild-type 
rat NTS1 including; S83G, A86L, T101R, H103D, H105Y, L119F, M121L, E124D, R143K, D150E, 
A161V, R167L, R213L, V234L, K235R, V240L, I253A, I260A, N262R, K263R, H305R, C332V, 
T354S, F358V, and S362A. Of these, H103D, H105Y, A161V, R213L, V234L, H305R and S362A 
are derived from the parental receptor in the StEPM303 library (NTS1-DO3) and thus the other 
18 mutations were acquired during the selection outlined in Figure 5.1. Figure 5.5 indicates the 
positions of these mutations on the crystal structure of NTS1-H4 [19]. 
 
5.1.5.  Discussion 
The critical advantage of CHESS over other techniques is that millions of GPCR-mutant-
containing microcapsules can be screened directly for the desired stability properties within an 
hour using FACS, Here we panned the StEPM303 library [29] for NTS1 mutants that were stable 
in short-chain detergents that are desirable for crystallization. In addition, we selected for 
stability over 24 h in such detergents, as well as receptors that exhibiting apo-state stability. We 
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believe such properties to be highly desirable for the application of the experimental methods 
commonly used for SBDD.  
The encapsulated cells were resistant to HTG over these time periods, and genes encoding 
highly stable NTS1 mutants could be isolated from the sorted capsules that exhibited high 
fluorescent ligand binding (Fig. 5.2). The clone that was able to bind the most fluorescent ligand 
after 2 h and 98 h solubilized in HTG, when measured using 2 different instruments, was termed 
NTS1-H4. NTS1-H4 exhibited all of the properties we were seeking, including high 
thermostability when heated in the presence and absence of ligand (Fig. 5.3A-B), and long-term, 
apo-state stability in detergent (Fig. 5.3C).  
Because NTS1 has been stabilized using several methods, we were able to directly 
compare the resultant receptors with the wild-type protein. NTS1-7m was stabilised using the 
systematic mutagenesis approach [26] and TM86V was derived through a combination of 
bacterial display for high expression and systematic mutagenesis [29]. Using a detergent 
mixture known to maintain unmodified rNTS1 in a stable state under mild conditions [38, 39], 
thermostability assays were performed on the 4 receptors (Fig. 5.3A-B). When heated in both 
the presence and absence of ligand, NTS1-H4 was the most thermostable, followed by TM86V, 
NTS1-7m and wild type. Compared to rNTS1, NTS1-H4 exhibited a 21.6 °C and 26.8 °C 
improvement in thermostability in detergent HTG when heated in the bound and apo-state 
respectively, the most stable by over 10 °C. NTS1-H4 also exhibited the highest stability of the 4 
receptors when incubated in this harsh detergent for over 21 h in the presence or absence of 
bound ligand (Fig. 5.3C).  
This high level of apo-state stability meant that we could successfully use bacterially 
expressed NTS1-H4, captured onto magnetic beads, in robotic fluorescence-based saturation and 
competition binding assays (Fig. 5.4). From fitting the saturation binding curves the Kd of the 
fluorescently labelled neurotensin analogue, Alexa-647-labelled neurotensin 8-13 (A647-NT), 
could be estimated to be 0.65 nM ± 0.13, which compares well to Ki values reported for 
unlabeled versions of this peptide using NTS1 expressing cells and tissues [40]. The high signal-
to-noise ratio in the saturation binding assays using this labelled peptide enabled us to conduct 
competition binding assays using a sub-saturating concentration of A647-NT (2 nM). Ki values 
for the binding of unlabeled NT8-13, NT1-12, SR48692 and SR142948 to NTS1-H4 were 
calculated from the resultant curves (Fig. 5.4C and Table 1). Calculated Ki values compared well 
to the literature values for NT8-13 [40], NT1-12 [41] and SR142948 [42], where cell culture and 
tissue preparations were used for NTS1 competition binding assays. This demonstrated that our 
engineered, bacterially expressed and detergent solubilized GPCR exhibited native-like ligand 
binding behavior.  
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Interestingly, the antagonist SR48692 was less potent at competing A647-NT binding to 
solubilized NTS1-H4, compared to wt NTS1 which was tested in cell-based binding studies, by a 
factor of between 2.7 and 44 fold, depending on the values cited in the literature [42-44]. The 
affinity of SR48692 to the thermostabilised NTS1 variant NTS1-GW5 was reduced even by 130-
200 fold when measured in insect cell membranes, whereas binding of the agonist to this 
receptor was unaltered [14]. NTS1-H4 and NTS1-GW5 share only one homologous stabilizing 
mutation at position 358 in TM7, which is a substitution from Phe to Ala in NTS1-GW5 and to Val 
in NTS1-H4. Mutation of this position to alanine has been reported to reduce the affinity of 
SR48692 for NTS1 but not that of neurotensin [44] and result in a constitutively active receptor 
with respect to inositol phosphate production [45], suggesting that the lower affinity of SR48692 
for both NTS1-H4 and NTS1-GW5 may be a result of the mutation at position 358. Overall, 
engineering NTS1-H4 to be detergent-stable in the apo-state has enabled us to 
pharmacologically characterize the orthosteric binding site of a detergent-solubilized GPCR 
using low cost, high-throughput compatible assays.  
Thermostabilization of NTS1 has so far resulted in the determination of 5 structures of 
different receptor variants or constructs. NTS1-GW5 was engineered using systematic 
mutagenesis [46], and the crystal structure of this receptor, produced in insect cells, was 
determined using the T4-lysozyme fusion and lipidic cubic phase crystallization approach [14]. 
The crystal structures of two NTS1-TM86V constructs, derived from directed evolution using 
bacterial display [29], were recently solved in detergent using vapor diffusion crystallization 
[19]. In the same study, the structures of two more receptors were determined, NTS1-G7 [31] 
and NTS1-H4 (engineered in this manuscript), which were stabilised using CHESS. Of note is that 
the structures of NTS1-TM86V, NTS1-G7 and NTS1-H4 were the first GPCR structures solved 
from bacterially expressed protein. Furthermore, the direct selection of NTS1-G7 and NTS1-H4 
for stability in short-chain detergents allowed these receptors to be crystallised in short-chain 
detergents using vapor diffusion crystallography without any systematic mutational 
optimization. TM86V was also crystallized in short chain detergents, but this receptor was 
generated after further systematic mutational optimization of clones selected using bacterial 
display which were very stable in milder detergents, but less stable in short-chain detergents 
[29].  
A thorough comparison of the 5 structures can be found in Egloff et al. [19]. While NTS1-
H4 is the most thermostable variant described to date, it also contains the most mutations. In 
Figure 5, the CHESS selected mutations in NTS1-H4 are highlighted in the crystal structure. 
Selected mutations were relatively evenly distributed across transmembrane domains (TMs) 1-3 
and TMs 5-7, with the most mutations occurring in TM5 (6 substitutions) (Fig. 5.5). NTS1-7m, 
NTS1-GW5, TM86V, NTS1-G7 and NTS1-H4 only share homologous stabilizing mutations at 
108 CHAPTER 5 
positions 86 (A86L) and 358 (F358A or V), indicating that stabilization can be achieved through 
a variety of mutational modes.  
In addition to structure determination, purified thermostabilized GPCRs have also proven 
to be useful tools for biophysical analysis of ligand binding and fragment screening [36, 37, 47]. 
For these types of studies it is highly beneficial to have apo-receptor samples that are stable in 
detergents over the long time periods needed to measure binding kinetics, and that won’t 
denature upon ligand dissociation. The engineering of NTS1-H4 is a demonstration of the utility 
of CHESS for evolving receptors with the properties needed to conduct biochemical and 
biophysical experiments on solubilized, purified GPCRs. 
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Table 5.1 Binding constants derived from competition binding experiments using solubilized NTS1-H4 
Ligand Fitted Constant nM SEM Figure 
NT8-13 Ki 0.34 0.09 5C 
NT1-12 Ki 306 77 5C 
SR48692 Ki 87 27 5C 
SR142948 Ki 0.5 0.1 5C 
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Figure 5.1  CHESS based selection workflow for generating NTS1 mutants that were resistant to short-
chain detergents, apo-state solubilization and long term incubations in the solubilized state. CHESS rounds 
are indicated by R1-3. For a diagrammatic representation of the CHESS method, see Scott et al. [31]. 
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Figure 5.2  Single clone analysis of 47 selected NTS1 mutants after 3 rounds of CHESS. Detergent-
solubilized, biotinylated receptors were captured onto streptavidin-coated magnetic beads. The ability of 
the receptor-coated beads to specifically bind HL-NT after 2 h (open columns) or 98 h (striped columns) 
in the short-chain detergent HTG was measured using a fluorescent plate reader (A), or an analytical 
cytometer (B). Clone 47, indicated with arrows, was termed NTS1-H4.  
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Figure 5.3  The stabilities of thermostabilized NTS1 mutants generated using different methods were 
compared to wild type NTS1. The thermostabilities of wild-type rat NTS1 (NTS1, filled circles with dotted 
lines), NTS1-7m (filled squares with solid lines), TM86V (filled triangles with dashed lines) and NTS1-H4 
(crosses with solid lines) were measured with the receptors heated in the presence of HL-NT (A) or in the 
apo-state (B). Apparent melting temperatures (Tm) were determined with non-linear regression and are 
displayed in parentheses next to the figure keys. (C) Long-term stability of the 4 receptors was assayed by 
measuring the relative levels of HL-NT binding 3 h after solubilization (filled columns), 21 h after 
solubilization, 18 h of which the receptors were incubated with HL-NT (open columns), or 21 h after 
solubilization incubated in the apo-state (chequered columns). The receptors were incubated at 4 °C. 
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Figure 5.4  Saturation (A-B) and competition (C) binding assays were performed on solubilized, 
biotinylated and sfGFP tagged NTS1-H4, immobilized on streptavidin-coated magnetic beads. For 
saturation binding (A), beads were exposed to increasing concentrations of A647-NT in the presence of 
excess NT8-13 (COMPETITION, open triangles, dashed line) or without competition (TOTAL BINDING, 
open circles, solid line). The ratio of A647-NT to sfGFP fluorescence was measured to account for slight 
differences in bead concentrations across the 96-well plates. (B) Potential ligand depletion was assayed by 
measuring the levels of A647-NT retained in the binding wells from (A) upon removal of the receptor 
coated beads. A decrease in A647-NT in total binding wells (black columns) compared to the competition 
wells (chequered columns), where unlabelled NT would saturate the receptor, would indicate depletion of 
A647-NT in the binding step. No ligand depletion was observed. For competition binding (C), NTS1-H4 
coated beads were exposed to 2 nM A647-NT and increasing concentrations of unlabelled NT8-13 (filled 
circles with solid line), NT1-12 (open circle with dashed line), SR48692 (filled triangles and solid line) and 
SR142948 (open squares with dotted line). The ratio of A647-NT to sfGFP fluorescence was measured, 
with the data sets normalised to 100% based on the fluorescence of wells containing no competitor. Mean 
values ± the standard error of the mean (SEM) are plotted from data pooled across 3 separate 
experiments. 
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Figure 5.5  Positions of CHESS-selected mutations in the crystal structure of NTS1-H4 displayed at two 
angles rotated by 90 degrees. TM1 is coloured dark blue, TM2 light blue, TM3 cyan, TM4 green, TM5 
yellow, TM6 orange, TM7 red and neurotensin purple. 
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5.2.  Abbreviations 
2YT  2x concentrated yeast tryptone medium 
AU   absorbance unit  
CHAPS  3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate 
CD  circular dichroism (spectroscopy) 
CHS  cholesteryl hemisuccinate 
DDM  n-dodecyl-β-D-maltopyranoside 
DM  n-decyl-β-D-maltopyranoside 
DNA  deoxyribonucleic acid 
DNase  deoxyribonuclease 
DTT  dithiothreitol 
EC  extracellular loop 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
FPLC  fast protein liquid chromatography 
GdnHCl  guanidine hydrochloride 
GPCR  G protein-coupled receptor 
GRK  GPCR kinase 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRV  human rhinovirus 
IC  intracellular loop 
IMAC  immobilized metal ion affinity chromatography 
IPTG  isopropyl-β-D-thiogalactoside 
KD  echilibrium dissociation constant 
kDa  kilo Dalton 
koff  dissociation rate constant 
kon  association rate constant 
MALS  multi-angle light scattering 
MBP  maltose binding protein 
MR  molecular replacement 
MSP  membrane scaffold protein 
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MW  molecular weight 
NG  n-nonyl-β-D-glucopyranoside 
NHS  N-hydroxysuccinimide 
Ni-NTA  nickel-nitrilotriacetic acid 
NM  n-nonyl-β-D-maltopyranoside 
NMR  nuclear magnetic resonance (spectroscopy) 
NT  neurotensin 
NTR1  neurotensin receptor 1 
OD  optical density 
OG  n-octyl-β-D-glucopyranoside 
OGNG  octyl glucose neopentyl glycol 
OTM  n-octyl-β-D-thiomaltopyranoside 
PCR  polymerase chain reaction 
pD  protein D from phage lambda 
PDB  Protein Data Bank 
PDB-ID  Protein Data Bank identification number 
PEG  polyethylene glycol 
RMSD  root mean square deviation 
RT  room temperature 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SEC  size exclusion chromatography 
SP  sulphopropyl 
Tm  midpoint of transition 
Tris  tris(hydroxymethyl)aminomethane 
TROSY  transverse relaxation-optimized spectroscopy 
TrxA  thioredoxin A 
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5.3.  Plasmid for large-scale expression of NTR1 variants 
 
Figure 5.6  This vector was originally obtained as a kind gift from Dr. Reinhard Grisshammer (pRG) and 
subsequently adapted according to this illustration. As a result of directed evolution, it contains a 
mutation in the origin of replication (C7054G, indicated by an asterisk), which increased the copy number 
by approximately 100% compared to the parent plasmid1. The NTR1 variants were inserted in between 
the two 3C protease sites using the restriction enzymes BamH1 and Cfr9I. The fusion protein MBP 
encodes a periplasmic signal sequence at the N-terminus of the construct. A deca-histidine tag follows the 
C-terminal TrxA fusion, but it is not required for the purification procedure developed in this work. 
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5.4.  Potential applicability of purification principles for other GPCRs 
 
Table 5.2 List of class A GPCRs with potential for analogous, ligand-based receptor purification. Only 
receptors binding to non-modified peptides without lysines were included. 
Receptor Gene Ligand Affinity Reference 
Type-1 angiotensin II receptor (human) AGTR1 DRVYIHPF Ki ≈ 1.47 nM 
2 
  RVYIHPF Ki ≈ 1.40 nM 
2 
Type-2 angiotensin II receptora AGTR2 DRVYIHPF Ki < 1 nM 
3; 4 
  RVYIHPF Ki < 10 nM 
3; 4 
B1 bradykinin receptor (human) BDKRB1 RPPGFSPL Ki ≈ 78 nM 
5; 6 
B1 bradykinin receptor (rat) Bdkrb1 RPPGFSPF Ki ≈ 15 nM 
3; 7 
  RPPGFSPL Ki ≈ 31 nM 
3; 7 
  ISRPPGFSPF Ki ≈ 46 nM 
3; 7 
B2 bradykinin receptor (human) BDKRB2 RPPGFSPFR IC50 ≈ 0.5 nM 
3; 8 
Neurotensin receptor 2 (human) NTSR2 RRPYIL Ki ≈ 1.4 nM 
9 
δ-type opioid receptor (human) OPRD YGGFL Ki ≈ 2 nM 
3; 10 
µ-type opioid receptor (human) OPRM1 YGGFL Ki ≈ 7 nM 
3; 10 
κ-type opioid receptor (human) OPRK1 YGGFLRRI Ki ≈ 0.2 nM 
3; 10 
a species not defined in references 
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